Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.1    
  

Registrant has requested confidential treatment of portions of this document. The portions for which Registrant seeks confidential treatment have been redacted and are
indicated by [  ]. Unredacted copies of the document have been filed with the Commission per Rule 24b-2.  

 SUPPLY AND DISTRIBUTION AGREEMENT  

    This Supply and Development Agreement (the "Agreement") is made as of the 21st day of September, 2001 (the "Effective Date"), by and between  SuperGen, Inc.,
("SuperGen"), a Delaware corporation, with its principal offices at 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, and  EuroGen Pharmaceuticals Ltd. ("EuroGen"), incorporated and registered in
England and Wales, Companies Act 1985 registration number 4157153, with
its principal offices at The Gloucestershire Innovation Centre, Southgate House, Southgate Street, Gloucester GL1 1UD, England. 

RECITALS:  

    WHEREAS, SuperGen is engaged in the business of developing, manufacturing, distributing and selling pharmaceutical products; 

    WHEREAS,
EuroGen desires to obtain, and SuperGen desires to grant to EuroGen, the right to apply for Regulatory Approval in various countries within the Territory, as described below,
and to promote, market, distribute and sell SuperGen's Products in such countries; 

    NOW,
THEREFORE, the Parties agree as follows: 

1.  DEFINITIONS  

    1.1 "Co-Exclusive Rights" means that any rights granted to EuroGen are likewise retained by SuperGen (or its
Third Party designee) so that EuroGen and SuperGen (or its Third Party designee) together jointly hold the exclusive rights so granted. 

    1.2 "Designated Receiving Point" means the place selected by EuroGen within England and approved by SuperGen, to receive
delivery of all shipments of Products hereunder. 

    1.3 "FDA" means the U.S. Food and Drug Administration or any successor entity thereto. 

    1.4 "Net Sales Revenue" means the gross revenue collected on a cash accounting basis by EuroGen and its Subdistributors
for sales of Products, less returned goods, allowances, amounts due any Subdistributor, and duties, excise taxes and shipping costs payable up to the point of delivery to the designated receiving
point within the Territory. If any non-cash consideration is received by EuroGen and/or its Subdistributors, the value shall be included in calculating gross revenue. 

    1.5 "Other Products" means any compounds or products not included in the SuperGen's Tier 1 Products, Tier 2 Products, or
Tier 3 Products that are developed or acquired by SuperGen [......] retains its
worldwide marketing rights. 

    1.6 "Party" or "Parties" means individually EuroGen or SuperGen and
collectively EuroGen and SuperGen. 

    1.7 "Product" or "Products" means any SuperGen compound or product for
which EuroGen has acquired rights to apply for Regulatory Approval, distribute and sell under Section 2 of this Agreement. 

    1.8 "Regulatory Approval" means all governmental approvals and authorizations necessary for the commercial sale of a
Product in a country within the Territory, including, but not limited to, marketing authorization, pricing approval and pricing reimbursement, as applicable. 

    1.9 "RFN Party" means that certain Third Party with which SuperGen, pursuant to a written agreement, has granted the
right of first discussion with respect to all pharmaceutical compounds, which are licensed to, owned by and/or developed by SuperGen. 

 

    1.10 "RFN Procedure" means the procedure outlined in the agreement with the RFN Party wherein SuperGen must offer the
RFN Party the right of first discussion before selling or granting any rights relating to any compound owned or developed by SuperGen. 

    1.11 "Specification" means the specification for a Product, as determined by SuperGen prior to the first commercial sale
of such Product, as may be modified from time to time as necessary. 

    1.12 "Subdistributor" means, with respect to a particular Product, a Third Party, including a wholesaler, who has
obtained through EuroGen, directly or indirectly, the right to distribute and/or sell Products. 

    1.13 "Territory" means Eastern and Western Europe and South Africa, including, without limitation, all countries now in
the European Union, countries admitted to the European Union during the term of this Agreement, Turkey, Norway, Switzerland, Czechoslovakia, Hungary, Poland, Romania, Bulgaria, Albania, and the
countries located within the geographic areas of the former Soviet Union and the former Yugoslavia. 

    1.14 "Third Party" means any natural person, corporation, partnership, joint venture, governmental authority, and any
other entity or organization, other than SuperGen or EuroGen. 

    1.15 "Tier 1 Product" means any pharmaceutical compound or product that is listed hereafter or contains the compounds
listed hereafter as an active ingredient: [  ]. 

    1.16 "Tier 2 Product" means any pharmaceutical compound or product that is listed hereafter, contains the compounds
listed hereafter as an active ingredient, or is derived from the application of any of the compounds listed hereafter:  [  ]. 

    1.17 "Tier 3 Product" means any pharmaceutical compound or product that is listed hereafter, contains the compounds
listed hereafter as an active ingredient, or is derived from the application of any the compounds listed hereafter:  [  ]. 

    1.15 "Year 1" means for each respective Tier 1 Product, Tier 2 Product or Other Product, the twelve month period
commencing on the date of the first sale of such Product within the Territory. "Year 2" shall be the twelve month period thereafter, and "Year 3" shall be the twelve month period after "Year 2." 

2.  APPOINTMENT  

    2.1  Exclusive Appointment to Tier 1 Products.  SuperGen hereby appoints and grants to EuroGen the
exclusive right to promote, market, distribute and sell Tier 1 Products [  ] within the Territory, and EuroGen
hereby accepts such appointment. EuroGen's sole authority shall be to obtain Regulatory Approvals for the Tier 1 Products  [  ] in the Territory, and promote, market, distribute and sell such
Tier 1 Products within the Territory. 

    2.2  Exclusive Appointment to Tier 2 Products subject to RFN.  In order to grant EuroGen rights in the
Tier 2 Products, SuperGen must first comply with the RFN Procedure by notifying the RFN Party and offering the right of first discussion regarding the terms proposed to be granted to EuroGen
hereunder. [  ], SuperGen hereby appoints and grants to EuroGen the exclusive right to promote, market,
distribute and sell within the Territory Tier 2 Products not granted to the RFN Party under the RFN Procedure, and EuroGen hereby accepts such appointment on the same terms and conditions contained
herein this Agreement. EuroGen's sole authority shall be to obtain Regulatory Approvals for such Tier 2 Products in the Territory, and promote, market, distribute and sell such Tier 2 Products within
the Territory. It is understood and agreed that SuperGen shall have no right to grant to EuroGen any rights to such Tier 2 Product on terms which, taken as a whole, are more favorable to EuroGen than
those terms offered by SuperGen to RFN Party, if any, without first offering such terms to RFN Party. 

2

 

    2.3  Co-Exclusive Appointment for Decitabine.  SuperGen hereby appoints and grants to EuroGen
the co-exclusive right to promote, market, distribute and sell Decitabine within the Territory, and EuroGen hereby accepts such appointment. EuroGen's sole authority shall be to obtain
Regulatory Approvals for the Decitabine in the Territory, and promote, market, distribute and sell Decitabine co-exclusively within the Territory. Notwithstanding the rights granted to
EuroGen with respect to Decitabine, in the event SuperGen wishes to sell and transfer rights in Decitabine to a Third Party and SuperGen, in its discretion, wishes to transfer such rights free of the
rights granted to EuroGen, SuperGen, in its sole discretion, may withdraw Decitabine from this Agreement effective on the date of the transfer by SuperGen of such rights. If SuperGen elects to
withdraw Decitabine from this Agreement, SuperGen shall reimburse EuroGen for any direct reasonable expenses incurred by EuroGen in connection with the development of Decitabine and with steps taken
to establish a marketing and distribution channel
in the Territory. Within thirty (30) days of such event, EuroGen shall provide SuperGen with an accounting of such expenses, and assign any Regulatory Approvals and/or other rights in
Decitabine to SuperGen. 

    2.4  Option to Obtain Appointment for Additional Products.  

    2.4.1  Grant of Options.  

    (a)  Option to Obtain an Exclusive Appointment to Tier 3 Products.  Subject to the availability of a
particular Tier 3 Product for exclusive appointment pursuant to Section 2.4.2, EuroGen shall have an option to obtain an exclusive appointment and grant to apply for Regulatory Approval and to
promote, market, distribute and sell such Tier 3 Products within the Territory. 

    (b)  Option to Obtain an Exclusive Appointment to Other Products.  Subject to the availability of a
particular Other Product for exclusive appointment pursuant to Section 2.4.2, EuroGen shall have an option to obtain an exclusive appointment and grant to apply for Regulatory Approval and to
promote, market, distribute and sell such Other Product within the Territory. 

    2.4.2  Availability.  SuperGen will notify EuroGen when a Tier 3 Product or Other Product (collectively,
the "Option Products") has reached a [  ] and has clinical data and documentation in sufficient quantity or
quality to enable EuroGen to apply for Regulatory Approval within the Territory. Within a ninety (90) days following the receipt of notice from SuperGen regarding such a status for one or more
of the Option Products, EuroGen shall notify SuperGen, with respect to the particular Option Product, whether EuroGen desires to obtain the right to apply for Regulatory Approval within one or more
countries within the Territory and to promote, market, distribute and sell such Option Product in one or more countries within the Territory. Subject to the RFN Party's right of first discussion
pursuant to the RFN Procedure, SuperGen shall notify EuroGen when such Tier 3 Product and/or Other Product is available for appointment to EuroGen. 

    2.4.3  Decline to License; Failure to Notify.  If EuroGen notifies SuperGen that it is not interested in
such Option Product, or if EuroGen fails to respond in writing to SuperGen within such ninety (90) day period, SuperGen shall have the right to promote, market, distribute and sell such Option
Product by itself, or grant any Third Party such rights, without restriction. 

    2.4.4  Exercise of Option.  

    (a) If
EuroGen notifies SuperGen that it desires to obtain the right to apply for Regulatory Approval and to promote, market, distribute and sell a particular Option
Product pursuant to Section 2.4.2,
following notice to the RFN Party in the manner described above, the Parties shall negotiate in good faith for a period of not less than ninety (90) days, or such longer period as the Parties
may otherwise agree, the grant of rights for such Option Product; 

3

 

such terms to be substantially similar to the terms set forth within this Agreement; however, the due diligence steps and requirements for such Products shall be mutually determined by the Parties at
such time. It is understood and agreed that SuperGen shall have no right to grant to EuroGen any rights to such Option Product on terms which, taken as a whole, are more favorable to EuroGen than
those terms offered by SuperGen to RFN Party, if any, without first offering such terms to RFN Party. 

    (b) If
EuroGen and SuperGen are unable to agree to the terms of such grant during such period, SuperGen shall have the right to promote, market, distribute and sell
such Option Product by itself, or grant any Third Party such rights, without restriction. 

    (c) To
the extent an Option Product has achieved "proof of concept" status, but does not yet have sufficient data and documentation to enable a filing for Regulatory
Approval, EuroGen may exercise its option under Section 2.4.4(a) to negotiate the terms of the grant of rights for such Option Product in order to accelerate the timing of Regulatory Approval
prior to the date specified in Section 2.4.2; provided, it is understood and agreed that such right of acceleration is subject to the RFN Party's right of first discussion pursuant to the RFN
Procedure. 

    2.5  Nipent for Oncology Applications.   SuperGen's rights to Nipent are subject to an agreement
currently held by Pfizer that grants rights to Nipent for oncology applications outside the United States. Discussions are currently underway to reacquire these rights in either SuperGen or EuroGen.
If such rights are reacquired by either Party, EuroGen shall bear the full cost and expense of acquiring such rights from Pfizer, and Nipent for all applications shall be considered a Tier 1 Product. 

    2.6  Subdistributors.  EuroGen may authorize Subdistributors to promote, market, distribute or sell
Products within the Territory in accordance with this Article 2. Within ten (10) days after the appointment of such Subdistributor, EuroGen shall notify SuperGen of (i) the
identity of such Subdistributor, (ii) the countries in the Territory in which the Subdistributor will distribute the Products, and (iii) the particular Products the Subdistributor
intends to distribute. EuroGen shall not sell or otherwise transfer Products to any Subdistributor until such Subdistributor enters into a form of written agreement ("Subdistributor Agreement") with
EuroGen, binding the Subdistributor to terms and conditions substantially similar to those terms and conditions agreed upon by EuroGen in this Agreement. EuroGen agrees to terminate a Subdistributor's
right to distribute Products promptly upon becoming aware that such Subdistributor is selling or otherwise distributing Products, directly or indirectly, in a manner that is not in accordance with the
provisions of this Article 2. EuroGen shall (i) use best efforts to ensure that such Subdistributors comply with the provisions of this Agreement and (ii) supervise the activities
of all Subdistributors. Each Subdistributor Agreement shall contain provisions making SuperGen a direct and intended Third Party beneficiary of such Subdistributor Agreement. 

    2.7  Limitation on Rights.  Notwithstanding the rights granted to EuroGen to promote, market, distribute
and sell Products under this Article 2, EuroGen shall have no right to (i) directly solicit sales, promote, market or sell Products outside the Territory, or (ii) solicit or
accept orders from persons or entities located outside the Territory. Furthermore, EuroGen agrees not to provide Products to any Third Party if EuroGen knows or has reason to know that Products
provided to such Third Party have been sold, or are intended for sale, outside of the Territory. 

    2.8  Reservation of Rights.  Except as expressly provided in this Article 2, no right, title or
interest is granted, whether express or implied, by SuperGen to EuroGen relating to other SuperGen products. Nothing in this Agreement shall be deemed to restrict SuperGen's right to exploit Products,
technology, know-how, patents or any other intellectual property rights, outside the Territory or in other products other than the Products. SuperGen reserves the right to appoint other
authorized distributors or resellers outside the Territory without restriction. It is further understood that subject to compliance 

4

 

with the provisions of this Section 2, SuperGen may promote, market, distribute and sell products other than those covered by this Agreement in the Territory, either directly or indirectly, for
any and all uses. 

    2.9  Non-Compete.  EuroGen shall pursue reasonable sales policies and procedures to realize
the maximum sales potential for the Products in the countries within the Territory described in the Regulatory and Marketing Plan. EuroGen agrees that any efforts by EuroGen to sell directly competing
products in the Territory would constitute a conflict of interest with respect to EuroGen's obligations to market the Products, and EuroGen warrants to SuperGen that it does not currently represent,
promote, market or sell any products that directly compete with the Products. During the terms of this Agreement, EuroGen shall not, and shall use commercially reasonable efforts to ensure that its
Subdistributors (other than wholesalers) do not, represent, promote, market or otherwise try to sell within the Territory any other products that substantially and/or directly compete with the
Products. If SuperGen believes that any other products being promoted, marketed or otherwise trying to be sold by EuroGen directly compete with a Product, the Parties shall negotiate in good faith for
a period of not less than ninety (90) days, or such longer period as the Parties may otherwise agree, for a resolution of the issue. If no resolution is achieved within such period, SuperGen
shall have the right, as its sole remedy hereunder, to either (i) terminate all rights of EuroGen to market, distribute and sell the particular Product that substantially and/or directly
competes with another product marketed by or on behalf of EuroGen, or (ii) convert the exclusive rights of EuroGen to market that Product into a non-exclusive right. In either case,
SuperGen shall be free to promote, market, distribute and sell such Product in the Territory directly or indirectly. 

    2.10  Sale Conveys No Right to Manufacture or Modify.  Products are offered for sale and are sold by
SuperGen subject in every case to the condition that such sale does not convey any license, expressly or by implication, to manufacture, modify, duplicate, or otherwise copy or reproduce any of the
Products. Notwithstanding the foregoing or anything elsewhere herein, if SuperGen fails to supply any Product as required hereunder to the extent of at least  [  ]of the forecasted requirements
for  [      ], after written notice
thereof, EuroGen shall have the limited right, but shall not be obligated, to have the Product manufactured and supplied by a Third Party to the extent necessary to fulfill its requirements. Such
limited right shall continue until SuperGen can reasonably demonstrate that it is able to supply adequately EuroGen's forecasted requirements for the Product. The costs thereof shall be due and
payable and may be offset from amounts otherwise due SuperGen hereunder. 

    2.11  Independent Contractors.  The relationship of SuperGen and EuroGen established by this Agreement is
that of independent contractors, and nothing contained in this Agreement shall be construed to (i) give either Party the power to direct and control the day-to-day
activities of the other, (ii) constitute the parties as partners, joint venturers, co-owners or otherwise as participants in a joint venture or common undertaking, or
(iii) allow EuroGen to create or assume any obligation on behalf of SuperGen for any purpose whatsoever. All financial and other obligations associated with EuroGen's business are the sole
responsibility of EuroGen. 

3.  REGULATORY APPROVAL AND CLINICAL DEVELOPMENT  

    3.1  Regulatory and Marketing Plan and Clinical Development.  

    3.1.1 Within
90 days from the date of this Agreement and annually thereafter, EuroGen shall submit to SuperGen a strategic plan ("Regulatory and
Marketing Plan") for obtaining Regulatory Approval for each Tier 1 Product and, when applicable, each Tier 2 Product, Tier 3 Product or Other Product for which the rights were granted to EuroGen under
Section 2. The Regulatory and Marketing Plan shall specify, on a country-by-country and Product-by-Product basis, the sequence of the
applications to be filed by EuroGen, the type of application to be filed (National Application, Mutual Recognition Application, Centralized Application), and an estimated timetable for the process.
SuperGen acknowledges that Regulatory Approval for all compounds and products 

5

 

covered by this Agreement will not be pursued concurrently and will not necessarily cover all countries within the Territory. Instead, they will be sequenced in time and in selected countries based on
a number of strategic factors, including the nature of the data collected by SuperGen and on the status of SuperGen's applications with the FDA. Once a Product has been commercialized, the Regulatory
and Marketing Plan shall include details on its marketing and promotion strategy, including an estimate of the minimum purchase requirements. SuperGen shall provide Data, time tables, indication
information, manufacturing lead times, shelf life, and other input for the preparation of the Regulatory and Marketing Plan. SuperGen shall have the right to participate in the preparation of, and
shall have the right to approve the Regulatory and Marketing Plan, which approval shall not be unreasonably withheld. The parties shall work together to agree on a Regulatory and Marketing Plan that
meets the goals and objectives of each Party. The parties acknowledge that EuroGen is not obligated to file for
Regulatory Approval or to promote, market, distribute and sell the Tier 1 Products or the Option Products in all countries within the Territory. In the event: (i) EuroGen does not wish to apply
for Regulatory Approval for any Product within certain countries in the Territory, (ii) does not wish to promote or market any Product within certain countries in the Territory, or
(iii) SuperGen wishes to have EuroGen file applications for Regulatory Approval in certain countries sooner than reflected in the Regulatory and Marketing Plan submitted by EuroGen, the parties
shall negotiate in good faith an alternative strategy. If the parties cannot otherwise agree on an alternative strategy, the rights granted to EuroGen for the specific Product involved shall become  
[      ] as to such countries. 

    3.1.2 Subject
to SuperGen's providing EuroGen with the Data and other information described in Section 3.3 below, EuroGen shall exercise its best efforts
to pursue, and shall bear the full cost and expense of, the Clinical Development of the Products to support Regulatory Approval in those countries within the Territory described in the Regulatory and
Marketing Plan. For purposes of this Agreement, "Clinical Development" includes, but is not limited to, all clinical studies and trials, and all safety, toxicology, efficacy, and other data required
to pursue, obtain and maintain Regulatory Approval in those countries specified in the Regulatory and Marketing Plan. In performing its obligations under this Article 3, EuroGen shall act in
accordance with Section 3.8 below, and in so doing EuroGen shall keep SuperGen fully apprised with respect to its Clinical Development activities and shall provide SuperGen with reasonable
advance opportunity for input regarding these activities, including the right to review and approve the protocols and audit reports relating to all clinical studies. 

    3.1.3 SuperGen
shall exercise commercially reasonable efforts, at its discretion, to pursue, and shall bear the full cost and expense of, the Clinical
Development of the Products to support Regulatory Approval in the United States. 

    3.2  Regulatory Approval.  EuroGen shall exercise its best efforts to file, obtain and maintain
Regulatory Approval for the Products in each country of Territory in the sequence and in the matter described in the Regulatory and Marketing Plan. Applications shall include a request for
reimbursement approval for the Product in the applicable countries (including but not limited to any and all applicable programs administered by government and private Third Party payers). EuroGen
shall bear the full cost and expense thereof, subject to SuperGen's providing, at its expense, one English translation copy of all Data, applications, protocol, dossier and other necessary information
obtained in connection with or filed as part of SuperGen's applications for FDA approval. EuroGen shall keep SuperGen fully apprised with respect to its regulatory and reimbursement activity in each
country of the Territory. 

    3.3  Reasonable Cooperation.  Each Party shall provide the other Party, at its cost and expense, all
reasonable assistance requested by the other Party with respect to the foregoing Regulatory and Marketing Plan, Clinical Development and regulatory activities, including, but not limited to, promptly
providing the other Party with any and all authorizations, approvals, certificates of free sale, and other 

6

 

information, documents, materials and assistance reasonably required by the other Party to file, obtain, and maintain Regulatory Approval for the Product. SuperGen shall provide on a timely basis and
from time to time, at its expense, one English translation copy of all Data, applications, dossier, protocol and other necessary information obtained in connection with or filed as part of SuperGen's
applications for FDA approval of each Tier 1 Product, Tier 2 Product, Tier 3 Product or Other Product for which rights are granted to EuroGen hereunder, to the extent not already provided under
Section 3.2. 

    3.4  Excused Performance.  The Parties acknowledge and understand that the development, obtaining of
Regulatory Approval, and marketing of the Products, as with any pharmaceutical product, is subject to certain inherent risks including that (a) the Products will be ineffective, toxic, or will
not receive Regulatory Approval, or will receive Regulatory Approval but with labeling which the Parties agree is insufficient to render the Product commercially viable; (b) the Products will
be too expensive to manufacture or market or will not achieve broad market acceptance; (c) Third Parties will hold proprietary rights that will preclude the marketing and sale of the Products;
or (d) Third Parties will market equivalent or superior products. Neither Party makes any representation or warranty that the Product (i) will be successfully developed; (ii) will
receive all necessary and/or commercially viable Regulatory Approvals, or (iii) will be commercially successful. The respective obligations of the Parties under this Agreement are expressly
conditioned upon the safety, efficacy and commercial feasibility of the Products, and, except as expressly provided herein, a Party's obligation hereunder shall be delayed or suspended for so long as
any condition or event exists which reasonably causes a Party to reasonably question the safety, efficacy or commercial feasibility of the Products. Each Party shall promptly notify the other Party in
the event any material issue arises as to the safety, efficacy, commercial feasibility, or adverse business or financial conditions with respect to any Product. 

    3.5  Global Harmonization; Redundant Activities.  Recognizing that the Products may be developed on a
global basis and that regulatory and budget efficiencies may be achieved through the worldwide use of appropriate data and files, the parties may seek, but shall not have the obligation, to design
mutually Clinical Development activities for applications of the Products in a manner to maximize global clinical and regulatory harmonization either (a) under an amendment to this Agreement,
or (b) under separate agreement. Without limiting the foregoing, except for SuperGen's obligation to furnish EuroGen one copy of Data, applications, dossier, protocol and other information
obtained in connection with or filed as part of SuperGen's applications for FDA approval, it is understood and agreed that EuroGen shall be responsible for all development costs for all clinical
activities that are necessary in the countries within the Territory described in the Regulatory and Marketing Plan. 

    3.6  Exchange of Data.  Subject to the provisions of this Article 3 and Article 9 below,
each Party shall have access to and the right to use for any purpose, any preclinical and/or clinical data and information obtained by the other Party with respect to Products; provided that EuroGen
agrees not to use or disclose to Third Parties any such data for purposes other than to perform this Agreement. Each Party will provide to the other Party reasonable access to all regulatory filings
made in the course of Clinical Development relating to preclinical and clinical trials and Regulatory Approvals by either Party or on such Party's behalf in any country with respect to each such
application of a Product, together with the underlying preclinical and clinical data, analysis, reports and correspondence (collectively with such filings, "Data"), at reasonable times, on reasonable
notice and (upon request) in English, to the extent each has the right to do so. 

    3.7  Disclosure of Data.  Subject to the provisions of this Article 3 and Section 9 below,
EuroGen and SuperGen may provide copies or summaries of Data prepared in connection with this Agreement to permitted Third Parties ((i) in the case of EuroGen, its subcontractors and
Subdistributors, and (ii) in the case of SuperGen, its sublicensees and subcontractors) (for purposes of this Section only, each a "Third Party Contractor") only to the extent reasonably
necessary for the development and commercialization of products, including without limitation the Products, in accordance with this Agreement. SuperGen and EuroGen shall each use good faith efforts to
obtain from such Third Party 

7

 

Contractors reasonable, prompt access to all Data prepared under the Clinical Development by or on behalf of such Third Party Contractors with respect to a Product at reasonable times, and in a
reasonable manner, with the right to provide such Data and/or access to SuperGen and its respective Third Party Contractors. However, if a prospective Third Party Contractor does not so agree to
provide or allow such access, the Party hereto proposing to enter into such agreement (the "Contracting Party") may enter into such agreement, but the Contracting Party shall not provide to such Third
Party Contractor, and such Third Party Contractor shall not have access to, any Data provided by the other of SuperGen or EuroGen (or such Party's Third Party Contractors). It is understood that the
foregoing shall include the right to disclose Data to Third Parties with whom EuroGen or SuperGen are discussing entering into agreements for such permitted purposes, subject to reasonable conditions
of confidentiality. 

    3.8  Review of Protocols, Clinical Studies, and Adverse Reports.  It is understood and agreed that all
Clinical Development activities to be conducted by or on behalf of EuroGen for the Products within the Territory must conform to FDA regulations and guidelines to the extent applicable to Products
sold outside the United States of America. In order to ensure conformance with such regulations and guidelines, EuroGen shall: (i) keep SuperGen reasonably informed as the status of the design
and conduct of any Clinical Development activities of such Products to be conducted by or on behalf of EuroGen, including without limitation, promptly providing to SuperGen any significant documents
that EuroGen receives from, or proposes to send to, a regulatory authority in the Territory, such as clinical trial proposals, amendments thereto and adverse event reports; (ii) provide
SuperGen with advance notice of meetings with any regulatory authorities and allow SuperGen to attend or participate in any such meeting; (iii) allow SuperGen representatives the opportunity to
audit any and all clinical sites and documentation for the Product; and (iv) permit any regulatory consultant designated and paid for by SuperGen (the "Consultant") to review such Clinical
Development activities in a consulting role. EuroGen shall cooperate with and assist SuperGen and the Consultant in connection with such activities, at SuperGen's request. In addition, EuroGen shall
consult with SuperGen and the Consultant on and accept SuperGen's reasonable proposed amendments and/or changes to, the design and conduct of such Clinical Development activities, in each case solely
to ensure conformance with such regulations and guidelines. 

4.  PROMOTION AND MARKETING  

    4.1  Promotional Effort.  EuroGen shall use its best efforts to promote and market the Products as
described in the Regulatory and Marketing Plan and shall transmit Product information and promotional materials to its customers, in order to maximize Product sales in the Territory. Such best efforts
shall include at least the following: (i) face-to-face sales presentations to appropriate health care professionals by sales representative including, without
limitation, discussions with health care professionals, meetings with or presentations to managed care entities, purchasing decision-makers or formulary committees of health care providers;
(ii) participation in conventions and continuing education programs; and (iii) conducting clinical trials and/or studies which are performed essentially for marketing purposes, expressly
excluding all clinical studies and trials which are required to pursue, obtain, and maintain Regulatory Approval in the Territory. Upon the first commercial sale of any Product in any country of the
Territory, EuroGen shall list the Products in its catalogs and make such Products available to its customers. 

    4.2  Materials.  EuroGen shall provide to SuperGen samples of all promotional, marketing, advertising,
exhibition, training and educational materials prepared by or on behalf of EuroGen and relating to the Products, for purposes of review and approval by SuperGen, at least four (4) weeks prior
to the date of intended commercial release of such materials or commencement of such programs. SuperGen shall use commercially reasonable efforts to provide to EuroGen, within ten 

8

 

(10) business days after receipt of such materials, any and all comments and suggestions relating to such materials. 

    4.3  Other Reporting.  EuroGen shall provide, at SuperGen's expense, within thirty (30) days after
publication, copies of any and all articles, manuscripts, abstracts or other literature relating to the Products generated by investigators or others in the Territory in each case to the extent
reasonably available to EuroGen. 

    4.4  Sales Force.  EuroGen shall cause its sales force, and all other employees and approved agents and
representatives, to comply with all applicable laws and regulations in connection with the promotion, marketing, distribution and sales of the Products in the Territory. 

5.  PROFIT SHARING  

    5.1  SuperGen's Percentage.  In consideration for the supply of Product by SuperGen to EuroGen, EuroGen
shall pay to SuperGen on a quarterly basis an amount ("SuperGen's Percentage") equal to
the following Applicable Percentage of the Net Sales Revenue for such Product in each country within the Territory where the Product is sold: 

	For Sales Made in Year
 
	 	"Applicable Percentage"

	Year 1	 	[      ]
	Year 2	 	[      ]
	Year 3 and beyond	 	[      ]

    5.2  Retail Price and Economic Unfeasibility.  The retail price for each Product ("RP") may be different
for each country where the Product is to be sold within the Territory and may be determined in connection with Regulatory Approval in each country. In most countries within the Territory, the RP
cannot be increased, but may be subject to reduction by governmental action. If despite EuroGen's best efforts, EuroGen is unable to sell a Product in one or more countries within the Territory at a
RP that will provide a reasonable profit to SuperGen, upon written notice from SuperGen, the Parties shall negotiate in good faith a new RP for the Product. Once agreed, EuroGen shall use its best
efforts to get the RP approved in the applicable country or countries. In the event the Parties are unable to agree to a new RP or the new RP cannot be approved, either Party may eliminate the Product
being sold in the applicable country or countries so long as all existing contractual supply obligations to Third Parties with respect thereto are met. EuroGen agrees that it will not enter into any
supply obligations in excess of twelve months without obtaining the prior written consent of SuperGen. 

    5.3  Minimum Purchases of Products to Maintain Exclusive License.  The parties recognize that there is
insufficient information available at this time to determine equitable minimum purchase requirements. [  ] after
commercialization of a Product within any country with the Territory, as part of the Regulatory and Marketing Plan, the parties shall include minimum quantities of such Product for  [  ] and
for each year thereafter. In order to maintain its exclusive right to distribute and sell the applicable
Product during the Term, EuroGen must purchase and sell to End Users the minimum quantities of the applicable Product in each year starting in  [  ] as agreed upon by the parties. If EuroGen
fails to make the agreed upon minimum purchases in any given year
starting in [  ], SuperGen shall have the right, at its sole discretion, to  [  ] EuroGen's appointment and right to market, distribute
and sell such Product. 

    5.4  Payment of SuperGen's Percentage.  EuroGen and its Subdistributors shall maintain accurate books and
records, which enable the calculation of amounts payable hereunder to be verified. EuroGen and its Subdistributors shall retain the books and records for each quarterly period for three
(3) years after the calendar quarter to which they pertain. Statements showing the calculation of Net Sales Revenue for each Product on a country-by-country basis within
the Territory and the amount of SuperGen's Percentage payable for such quarter shall be prepared by EuroGen in accordance with the 

9

 

provisions of this Agreement and shall be delivered the statements to Seller on a quarterly basis, no later than 30 days following the applicable calendar quarter. All payments by EuroGen of
SuperGen's Percentage, with respect to any Product, shall be made within thirty (30) days after the end of the calendar quarter in which the sale of the Product occurred. All amounts payable to
a Party hereunder shall be payable in United States Dollars and shall be made by check or bank wire transfer in immediately available funds to an account designated by the respective Party. 

    5.4.1  Currency Conversion.  If any currency conversion shall be required in connection with the payment
of any amounts due hereunder, such conversion shall be made by using the daily exchange rate for the purchase of U.S. dollars designated by EuroGen's U.K. bank on the date when such payment becomes
due. 

    5.4.2  Late Payments.  Any payments due under this Agreement not received by the date such payments are
due under this Agreement shall bear interest, to the extent permitted by applicable law, at the U.S. prime rate per annum quoted in the "Money Rates" column of the Wall Street
Journal (U.S., West Coast Edition) on the due date of such payment, plus an additional two percent (2%), calculated on the number of days such payment is delinquent. This
Section 5.4.2 shall in no way limit any other remedies available to either Party hereto. In the event that EuroGen's account becomes more than sixty (60) days overdue, SuperGen may, in
its sole discretion, require that EuroGen deliver an irrevocable letter of credit from a major commercial bank to secure payments to be payable thereafter. Such letter of credit shall be delivered to
SuperGen at least thirty (30) days prior to any further requested delivery. In such case, SuperGen shall have no obligation to deliver any additional Products until it receives such letter of
credit from EuroGen. 

    5.5  Taxes.  

    5.5.1 Up
to the point of delivery of the Product to the Designated Receiving Point, SuperGen shall be responsible to pay any export taxes or export duties
imposed by any governmental agency. From and after the point of delivery of the Product to the Designated Receiving Point, EuroGen shall bear all governmental taxes and duties relating to the Products
(including, without limitation, import taxes and duties, sales, withholding, value-added and similar taxes, but excluding taxes on the net income of SuperGen). 

    5.5.2 All
payments by EuroGen specified hereunder (including those under this Article 5) are expressed as net amounts and shall be made free and clear
of, and without reduction for, any withholding taxes. EuroGen shall provide SuperGen with official receipts issued by the appropriate taxing authority or such other evidence as is reasonably requested
by SuperGen to establish that such taxes have been paid. If SuperGen uses a foreign tax credit received by SuperGen as a result of the payment of withholding taxes by EuroGen and thereby reduces the
amount of U.S. income tax that SuperGen otherwise would have paid, SuperGen shall refund to EuroGen the amount of such reduction with respect to such foreign tax credit. 

    5.6  Audit of Records.  Upon thirty (30) days prior notice to EuroGen, independent accountants
selected by SuperGen and reasonably acceptable to EuroGen, may have access to the books and records of EuroGen and its Subdistributors during normal business hours to conduct a review or audit,
solely, however, to the extent necessary for the purpose of verifying the accuracy of EuroGen's payments and compliance with this Agreement. Any such inspection or audit shall be at SuperGen's
expense; however, in the event an inspection reveals underpayment of five percent (5%) or more in any audit period, EuroGen shall pay the costs of the inspection. Furthermore, EuroGen shall promptly
pay to SuperGen any underpayment with interest from the date such amount(s) were due, at the prime rate of interest as reported in Wall Street Journal
for the date of the accountant's report which reveals such underpayment. 

10

   6.  SUPPLY  

    6.1  EuroGen's Obligations.  

    6.1.1 EuroGen
shall use its best efforts to seek Regulatory Approval and to distribute the Products in those countries within the Territory and in the sequence
outlined in the Regulatory and Marketing Plan. EuroGen shall be solely responsible, at its expense, for all activities ancillary thereto (including, without limitation, warehousing and shipping after
receipt of the Product in the designated receiving point within the Territory). 

    6.1.2 Subject
to Section 2.10, EuroGen shall exclusively purchase from SuperGen or from its designated Third Party manufacturer(s), EuroGen's
requirements for the Products in the Territory so long as SuperGen uses its diligent efforts to ship quantities of Products on the dates specified in EuroGen's Purchase Orders to the extent such dates
are consistent with the forecasted quantities that EuroGen is obligated to supply pursuant to Section 6.3. 

    6.2  Terms and Conditions.  All supply of Products hereunder shall be subject to the terms and conditions
of this Agreement. ANY ADDITIONAL OR INCONSISTENT TERMS OR CONDITIONS OF ANY ORDER OR ACKNOWLEDGMENT GIVEN OR RECEIVED REGARDING THE SUBJECT MATTER OF THIS AGREEMENT SHALL HAVE NO EFFECT AND SUCH
TERMS AND CONDITIONS ARE HEREBY EXPRESSLY EXCLUDED. 

    6.3  Forecasts.  At least four (4) calendar months prior to commercialization of the first Product
in the Territory, and thereafter at least four (4) calendar months prior the start of each calendar quarter ("Q1"), EuroGen, shall provide SuperGen with a rolling written forecast of the
quantities of Product estimated to be required, on a calendar month-by-calendar month basis, during Q1 and the next three (3) calendar quarters ("Q2", "Q3" and "Q4",
respectively). Each such forecast ("Forecast") shall take into account input obtained from SuperGen, including the lead-time for manufacturing of the applicable Product and the product
shelf life for such Product. Based on this input, the Forecast shall indicate the estimated quantities of Product and shall specify the Designated Receiving Point. 

    6.4  Purchase Orders.  Together with each Forecast submitted under Section 6.3 above (the "Current
Forecast"), EuroGen shall place its Purchase Order with SuperGen, setting forth the quantity of Product to be delivered in each calendar month of the applicable quarter, the delivery dates to the
Designated Receiving Point. SuperGen shall accept such orders from EuroGen and shall promptly fill such Purchase Order on a timely basis and deliver the Product so ordered to the designated receiving
point within the Territory in compliance with the terms and conditions of this Agreement. SuperGen shall not be obligated to accept orders for any particular calendar month to the extent that the
quantity ordered for delivery in such month exceeds [      ]of the quantity of such Product forecast for such month
of the Current Forecast. SuperGen shall undertake efforts to fill orders for any such excess quantities from available supplies as the Parties mutually agree. 

    6.5  Form of Order.  All of EuroGen's orders shall be made pursuant to a written purchase order which, in
a form mutually agreed upon by the Parties, shall provide for shipment in compliance with the terms of this Agreement. SuperGen shall notify EuroGen within twenty (20) days from receipt of an
order of an inability to fill any amounts of such order on a timely basis. 

    6.6  Product Packaging and Labeling.  Unless otherwise agreed upon by the parties in writing, SuperGen
shall manufacture or cause to be manufactured Products in finished dosage form, including required labeling, carton and packaging, and shall deliver the finished Products to the receiving point within
the Territory designated by EuroGen. EuroGen shall not repackage or re-label the Products supplied to EuroGen by SuperGen hereunder without the prior written consent of SuperGen, which
consent shall not be unreasonably withheld. 

11

 

    6.7  Delivery.  All Products delivered pursuant to the terms of this Agreement shall be suitably packed
for shipment in SuperGen's standard containers, marked for shipment to the Designated Receiving Point and shipped EXW (Incoterms 2000). When received at the Designated Receiving Point, the risk of
loss shall pass to EuroGen. SuperGen shall provide confirmation of shipping to EuroGen. EuroGen has the right to select the carrier, but if it does not provide notice to SuperGen of its preferred
carrier on or before three (3) days prior to the shipment date, SuperGen may select the carrier. EuroGen agrees to undertake all formalities required to import the Products to the Designated
Receiving Point. All freight, insurance, and other shipping expenses to the Designated Receiving Point shall be paid by SuperGen. EuroGen shall bear all import duties and other applicable taxes for
importation into the Designated Receiving Point. With respect to exact shipping dates of Products, SuperGen shall use its best efforts to ship quantities of Products on the dates specified in
EuroGen's purchase orders submitted in accordance with this Article 6 to the extent such dates are consistent with the forecasted quantities that SuperGen is obligated to supply hereunder. 

    6.8  Inventory.  Subject to the receipt of Product from SuperGen in accordance with this
Article 6, EuroGen shall use its reasonable efforts to maintain adequate inventories of the Product in the Territory to meet the needs of its customers on a timely basis based upon, among other
factors, previous demand histories and seasonal trends, and any customers' contractual commitments. 

    6.9  Warranty, Inspection and Rejection.  

    6.9.1  Product Warranty.  SuperGen represents and warrants that all Products supplied to EuroGen
hereunder will comply with all applicable Specifications at the time of receipt at the Designated Receiving Point. In the event that any Product fails to comply with the Specifications at the time of
receipt by EuroGen, SuperGen shall, at SuperGen's own cost (including freight and insurance), deliver replacement quantities of such Products to EuroGen as soon as commercially reasonable or if not
able to replace, then debit SuperGen's account. SuperGen may analyze any Products rejected for nonconformity. In case of a disagreement between the Parties, the claim shall be submitted for tests and
decision to an independent testing organization mutually agreed upon by the Parties (the "Laboratory"). The Laboratory shall comply with appropriate current Good Laboratory Practices as defined by the
FDA from time to time. The appointment of the Laboratory shall not be unreasonably withheld or delayed by either Party. The determination of the Laboratory with respect to all or part of any shipment
of Products shall be final and binding upon the Parties. The fees and expenses of the Laboratory shall be paid by the Party against whom the determination is made. SuperGen's Product warranties shall
not apply to Product that has been modified or altered in any manner by anyone other than SuperGen or EuroGen (or their respective Subdistributors), or to defects caused (i) through no fault of
SuperGen or EuroGen (or their respective Subdistributors), during shipment, (ii) by accident, negligence or misuse on the part of anyone other than SuperGen or EuroGen (or their respective
Subdistributors) or (iii) by storage, handling, or usage in any manner inconsistent with the approved Product labeling. 

    6.9.2  Product Inspection.  EuroGen shall, promptly upon receipt of each shipment perform customary
inspection. Any claim regarding the failure of such shipment to conform to the applicable Specifications shall be submitted to SuperGen promptly upon discovery, together with reasonable evidence of
such nonconformity, but in no case later than the longer period of (i) thirty (30) business days after receipt of the shipment, or (ii) the length of time reasonable required to
perform the tests mandated by regulatory authorities. Any Product supplied by SuperGen under this Agreement which fails to conform to the applicable Specifications shall be subject to the provisions
of this Agreement. SuperGen shall give EuroGen written instructions how EuroGen should dispose, at SuperGen's expense, of any non-conforming Products. In the event SuperGen elects to have
EuroGen return the nonconforming goods to SuperGen, such Products shall be subject to the return procedure in this Article 6. 

12

 

    6.9.3  Discrepancies.  All shipments, and all shipping and other charges, shall be deemed correct unless
SuperGen receives from EuroGen, no later than the longer period of (i) thirty (30) business days after receipt of a given shipment, or (ii) the length of time reasonable required
to perform the tests mandated by regulatory authorities, a written notice specifying the shipment, the transfer order number, and the exact nature of the discrepancy between the order and the
shipment, or the nature of the discrepancy in the shipping or other charges, as applicable. Rejected Products shall be subject to the provisions of this Article 6. 

    6.10  Return Procedure.  If EuroGen wishes to return a Product to SuperGen, it shall request a Return
Material Authorization ("RMA") number from SuperGen. Within five (5) business days of receiving an RMA number, EuroGen shall return such Product accompanied by such RMA number, provided that in
no event shall such return occur later than thirty (30) days after the invoice date. Any Product returned to SuperGen by EuroGen as authorized under this Agreement shall (i) be shipped,
properly insured, freight prepaid, DDP (Incoterms 2000) SuperGen's facility in California, United States of America or such other location as SuperGen may designate in writing, (ii) packed in
its original packing material or the equivalent with the RMA number prominently displayed, and (iii) shall include any documentation or information requested by SuperGen. SuperGen may refuse to
accept returns of any Product not packed and shipped as provided in this Article 6. 

    6.11  Quality Controls.  EuroGen shall institute quality controls in accordance with, and shall comply
with, applicable laws and regulations and generally accepted industry standards (including cGMPs as defined below) for the storage, shipment, handling and distribution of the Products and shall define
responsibilities for key quality systems and a quality manual agreed to by both Parties and shall comply with all applicable laws and regulations relating to the storage, shipment, handling and
distribution of the Products. SuperGen shall have the right to audit all facilities used by the EuroGen to fulfill their obligations under this Agreement. For the purposes of this Agreement, "cGMPs"
means all applicable standards relating to manufacturing practices for intermediates, bulk products, or finished pharmaceutical products (i) promulgated in the form of laws or regulations by
the FDA or its counterpart governmental agencies or entities in the EU and/or a country within the Territory or (ii) promulgated by the FDA or its counterpart governmental agencies or entities
in the EU and/or a country within the Territory in the form of guidance documents (including, but not limited to, advisory opinions, compliance policy guides and guidelines) which guidance documents
are being implemented within the pharmaceutical manufacturing industry for such products. 

7.  ADVERSE EVENTS, COMPLAINTS AND OTHER REGULATORY MATTERS  

    7.1  Adverse Reaction Reporting.  EuroGen shall keep SuperGen informed of information in or coming into
its possession or control concerning side effects, injury, toxicity or sensitivity reaction and incidents of severity thereof associated with commercial and clinical uses, studies, investigations or
tests of each Product within the Territory, whether or not determined to be attributable to the Product. SuperGen shall be responsible for filing with the FDA, as required pursuant to 21 C.F.R. Sec.
314.80, any adverse reaction reports that it receives. EuroGen shall be responsible for filing with the appropriate regulatory authorities in each country within the Territory, where required, any
adverse reaction reports that it receives. 

    7.2  Product Complaints and Inquiries.  

    7.2.1 Any
medical or technical Product-related inquiries from consumers, physicians or other Third Party customers who reside within the Territory shall be
handled by EuroGen. SuperGen shall supply EuroGen with copies of its standard response information for the Product as well as any updates thereto. EuroGen shall use such information to respond to any
such inquiries from the Territory. EuroGen shall prepare and maintain a database containing responses to such inquiries from consumers, physicians or other Third Party customers who reside in the
Territory for 

13

 

which it is responsible, and shall make the contents available to SuperGen promptly upon SuperGen's request. 

    7.2.2 EuroGen
shall maintain a record of all complaints or reports of an actual or potential failure of any Product to meet the specifications set forth in
regulatory filings or in agreements among the Parties. 

    7.3  Product Recall.  In the event either Party determines that an event, incident or circumstance has
occurred that may result in the need for a recall or other removal of any Product, or any lot or lots thereof, from the market in the U.S. or within the Territory, such Party shall advise the other
Party and the Parties shall consult with respect thereto. SuperGen shall have the sole authority to decide whether to commence, and the sole responsibility for the handling and disposition of, a
recall or other removal of such Product in the U.S. EuroGen shall have the sole responsibility to decide whether to commence, and the sole responsibility for the handling and disposition of, a recall
or other removal of such Product within the Territory. Any such recall or other removal, by either Party, shall occur pursuant to a procedure to be determined by SuperGen with the input of EuroGen.
Except as provided below, if a Product (or any lot or lots thereof) is recalled or otherwise removed from the market, the costs and expenses of such recall or removal, including, without limitation,
expenses and other costs or obligations to Third Parties, the cost and expense of notifying customers and the costs and expenses associated with shipment of the recalled Product and the cost and
expense of destroying the Product removed from the market, if necessary, except as provided below shall be borne by SuperGen to the extent such costs and expenses relate to the United States and shall
be borne by EuroGen to the extent that such costs and expenses relate to the Territory. In the event that such recall or removal costs, expenses or obligations result solely from EuroGen's:
(i) improper or negligent distribution, storage or shipment of the Product, (ii) co-promotion, promotion or marketing of the Product in a manner inconsistent with the
Product's labeling, or (iii) violation of this Agreement, such costs, expenses and obligations shall be borne solely by EuroGen. 

    7.4  Governmental Contact Reporting.  EuroGen shall promptly notify SuperGen upon being contacted by the
FDA, or any other competent governmental authority or agency within the Territory, for any material regulatory purpose pertaining to this Agreement or to any Product for which Regulatory Approval has
been obtain. Excepting routine matters and matters relating to applications for Regulatory Approval, EuroGen shall not respond to the authority or agency before consulting with the SuperGen, unless
under the circumstances pursuant to which the authority or agency contacts such Party, it is not practical or lawful for EuroGen to give SuperGen advance notice. In any event, EuroGen shall inform
SuperGen of such contact as soon as practical and lawful. Each Party shall keep
the other Party advised with respect to information concerning the safety or efficacy of any Product, including but not limited to providing, within three (3) business days of the creation or
receipt thereof, all information regarding such safety, efficacy and medical information issues and copies of safety reports filed with the FDA or any other authority or agency. 

8.  TRADEMARKS  

    8.1  Limited Trademark License.  Subject to the terms of this Agreement, SuperGen hereby grants to
EuroGen a nonexclusive limited license within the Territory to use SuperGen's name and logo. 

    8.2  Use of Trade Names and Logos.  EuroGen recognizes that the name and logo of SuperGen represents a
valuable asset of SuperGen and that substantial recognition and goodwill are associated with SuperGen's name and logo. During the term of this Agreement, EuroGen shall have the right, but shall not be
obligated, to indicate to the public that it is an authorized distributor of the Products. EuroGen may advertise, promote, and market (within the Territory) such Products with SuperGen's trademarks,
marks, and trade names identified on Exhibit A provided by SuperGen to EuroGen, or as modified by SuperGen pursuant to this Article 8 (collectively, the "Trademarks"). SuperGen reserves 

14

 

the right to modify Trademarks or substitute alternative marks for any or all of the Trademarks at any time upon thirty (30) days prior written notice to EuroGen. The rights to the Trademarks
granted under this Article 8 shall automatically terminate on termination or expiration of this Agreement. Except as set forth in this Article 8, nothing contained in this Agreement
shall grant to EuroGen any right, title or interest in the Trademarks, whether or not specifically recognized or perfected under applicable laws, and EuroGen irrevocably assigns to SuperGen all such
right, title, and interest, if any, in any Trademarks. EuroGen shall not alter, remove or cover any Trademark applied to the Products by SuperGen, unless solely necessary to comply with applicable
law. At no time during or after the term of this Agreement shall EuroGen challenge or assist others to challenge the Trademarks or the registration thereof, or attempt to register any trademarks,
marks or trade names confusingly similar to those of SuperGen. Notwithstanding anything to the contrary, EuroGen may use its own name and trademarks in connection with the marketing and promotion of
the Products within the Territory. 

    8.3  Approval of Representations.  All representations of the Trademarks that EuroGen intends to use
shall first be submitted to SuperGen for approval (which shall not be unreasonably withheld) of design, color, and other details, or shall be exact copies of those used by SuperGen. EuroGen agrees to
fully comply with all reasonable guidelines, if any, communicated by SuperGen concerning use of the Trademarks. EuroGen shall have the right to promote, market, distribute and sell the Products under
trademarks, trade names and logotypes of EuroGen selected by EuroGen, which trademarks, trade names and logotypes shall be and shall remain the property of EuroGen. If any of SuperGen's
Trademarks are to be used in conjunction with another trademark on or in relation to the Products, the Trademarks shall be presented legibly, prominently and of reasonable size, but nevertheless
separated from the other mark so that each appears to be a mark in its own right, distinct from the other mark. 

    8.4  Injunctive Relief.  EuroGen acknowledges that a violation of this Article 8 would cause
irreparable harm to the SuperGen for which no adequate remedy at law exists, and EuroGen therefore agrees that, in addition to any other remedies available, and notwithstanding any other provision in
this Agreement, SuperGen shall be entitled to injunctive relief to enforce the terms of this Article 8. The prevailing party in any such action shall be entitled to recover all costs and
expenses, including reasonable attorney's and other professional fees and expenses incurred because of any legal action arising in relation to this Article 8. 

    8.5  Notification of Infringement and Enforcement.  EuroGen shall notify SuperGen of any infringement or
misuse of SuperGen's Trademark(s) of which EuroGen becomes aware. SuperGen shall be solely responsible for prosecution and enforcement of any infringement of the SuperGen Trademark(s). 

9.  CONFIDENTIALITY  

    9.1  Confidentiality Information.  EuroGen and SuperGen (the "Receiving Party") shall keep strictly
confidential any information disclosed in writing, orally, visually or in any other manner by the other Party (the "Disclosing Party") or otherwise made available to the Receiving Party which the
Disclosing Party considers to be and treats as proprietary or confidential ("Confidential Information"). Without limiting the generality of the foregoing, all proprietary information concerning the
Disclosing Party's business, operations, suppliers, products, product manufacture, sale, marketing or distribution, trade secrets and intellectual property shall be considered Confidential Information
by the Receiving Party. Any data or other information relating to or resulting from the clinical trials of the Product shall be deemed to be Confidential Information of SuperGen. The Disclosing Party
shall use commercially reasonable efforts to designate any written Confidential Information disclosed to the other Party as Confidential Information by prominently marking it "confidential", provided
that the failure to so mark 

15

 

shall not exclude such written information from the provisions of this Article 9. Confidential Information shall not include information which: 

    (a) is
or becomes generally available to the public other than as a result of unauthorized disclosure thereof by the Receiving Party; 

    (b) is
lawfully received by the Receiving Party on a non confidential basis from a Third Party that is not itself under any obligation of confidentiality or
nondisclosure to the Disclosing Party or any other Person with respect to such information; 

    (c) by
written evidence can be shown by the Receiving Party to have been independently developed by or for the Receiving Party; or 

    (d) is
established by competent proof that was in the possession of the Receiving Party at the time of disclosure by the other Party and was not acquired, directly or
indirectly from the other Party under any obligation of confidentiality. 

    9.2  Nondisclosure of Confidential Information.  The Receiving Party shall use Confidential Information
solely for the purposes of this Agreement and shall not disclose or disseminate any Confidential Information to any Third Party at any time without the Disclosing Party's prior written consent, except
for disclosure to those of its directors, officers, employees, accountants, attorneys, advisers, agents and representatives whose duties reasonably require them to have access to such Confidential
Information, provided that such directors, officers, employees, accountants, attorneys, advisers, agents and representatives are required to use the Confidential Information solely for purposes of
this Agreement and maintain the confidentiality of such Confidential Information to the same extent as if they were Parties hereto. 

    9.3  Exception.  The foregoing confidentiality and nondisclosure obligations shall not apply to
information which is required to be disclosed by law or by regulation, provided that (i) the Receiving Party gives the Disclosing Party reasonable advance notice of the disclosure, to the
extent reasonably practicable and legally permissible; (ii) the Receiving Party uses reasonable efforts to resist disclosing the Confidential Information; (iii) the Receiving Party
reasonably cooperates with the Disclosing Party on request to obtain a protective order or otherwise limit the disclosure; and (iv) upon the reasonable request of the Disclosing Party, the
Receiving Party shall provide a letter from its counsel confirming that the Confidential Information is, in fact, required to be disclosed. 

    9.4  Confidential Terms/Publicity.  Except as expressly provided herein, each Party agrees not to
disclose any financial terms of this Agreement to any Third Party without the consent of the other Party, except as required by securities or other applicable laws, in which case the Disclosing Party
shall seek confidential treatment to the extent available, or on a strict need to know basis to actual or prospective investors, or to a Party's accountants, attorneys and other professional advisors,
under conditions that reasonably protect the confidentiality thereof. Notwithstanding the foregoing, the Parties shall agree upon and issue a press release announcing the execution of this Agreement
and describing the relationship of the Parties under the Agreement. In addition, each Party may disclose to Third Parties the information disclosed in such press release without the need for further
approval by the other Party. 

10.  REPRESENTATIONS AND WARRANTIES  

    10.1  General.  Each Party represents, warrants and covenants to other that (i) it has the full
right, power, and authority to enter into this Agreement, grant the rights granted herein, and perform its obligations hereunder; (ii) it has not previously granted and will not grant any
rights in conflict with the rights granted herein; and (iii) it shall comply with the requirements of any and all applicable federal, state, local, foreign and other laws, regulations, rules
and orders of any governmental body having jurisdiction over such Party or the activities of such Party contemplated by this Agreement. 

16

 

    10.2  Disclaimer of Warranties.  EXCEPT AS PROVIDED IN THIS ARTICLE 10, NEITHER PARTY MAKES ANY
WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE
INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

11.  INDEMNIFICATION  

    11.1  EuroGen's Indemnification.  EuroGen agrees to indemnify, defend and hold SuperGen, and its
officers, employees and agents (each a "SuperGen Indemnitee"), harmless against any liability, demand, damage, cost or expense (including reasonable attorney's fees) arising from any Third Party claim
to the extent such claim is attributable to EuroGen's failure to perform its obligations hereunder or EuroGen's misconduct or negligence in the shipment, storage, handling, promotion, marketing,
distribution and sale of the Products. 

    11.2  SuperGen's Indemnification.  Except for claims for which EuroGen is obligated to indemnify under
Section 11.1, SuperGen agrees to indemnify, defend and hold EuroGen and its respective officers, employees and agents (each a "EuroGen Indemnitee"), harmless against any liability, demand,
damage, cost or expense (including reasonable attorney's fees) arising from any Third Party claim to the extent such claim is attributable to (i) a defect of the Products or the failure of the
Products to meet the Specifications or (ii) a failure of SuperGen to perform its obligations hereunder or SuperGen's misconduct or negligence in the manufacturing, shipment, storage, or
handling of the Products. 

    11.3  Procedures.  A Party (the "Indemnitee") that intends to claim indemnification under this
Article 11 shall promptly notify the other Party (the "Indemnitor") in writing of any claim, complaint, suit, proceeding or cause of action in respect of which the Indemnitee intends to claim
such indemnification (for purposes of this Section 11.3, each a "Claim"), and the Indemnitor shall have sole control of the defense and/or settlement thereof; provided that the Indemnitee shall
have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The indemnification under this Article 11 shall not apply to
amounts paid with respect to settlement of any Claim if such settlement is effected without the consent of the Indemnitor, which consent will not be unreasonably withheld or delayed. The failure to
deliver written notice to the Indemnitor within a reasonable period of time after the commencement of any such claim, suit or proceeding, if prejudicial to its ability to defend such action, shall
relieve such Indemnitor of any liability to the Indemnitee under this Article 11, but the omission to so deliver written notice to the Indemnitor shall not relieve the Indemnitor of any other
liability to the Indemnitee not covered under this Article 11. Without limiting the foregoing, the Indemnitee shall keep the Indemnitor fully informed of the progress of any Claim for which it
intends to claim indemnification under this Article 11. It is understood that only SuperGen may claim indemnity under this Article 11 (on its own behalf or on behalf of an SuperGen
Indemnitee), and other SuperGen Indemnitees may not directly claim indemnity hereunder. Likewise, it is understood that only EuroGen may claim indemnity under this Article 11 (on its own behalf
or on behalf of a EuroGen Indemnitee), and other EuroGen Indemnitees may not directly claim indemnity hereunder. 

12.  LIMITATION OF LIABILITY  

EXCEPT
AS OTHERWISE PROVIDED, NEITHER PARTY SHALL BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT OR CONSEQUENTIAL ARISING OUT OF OR RELATING TO THIS AGREEMENT; PROVIDED HOWEVER, THIS LIMITATION SHALL
NOT APPLY TO LOSSES ARISING FROM THIRD PARTY CLAIMS FOR WHICH A PARTY IS INDEMNIFIED UNDER THE TERMS OF THIS AGREEMENT. 

17

 

13.  TERM AND TERMINATION  

    13.1  Term.  The term of this Agreement shall commence on the Effective Date and, unless terminated
sooner in accordance with this Article 13, the term of this Agreement shall expire fifteen (15) years after the date of Regulatory Approval of the Product in the first country within the
Territory. 

    13.2  Termination for Material Breach.  Either Party may, in addition to any other remedies available to
it by law or in equity, terminate this Agreement, upon [  ] written notice to the other Party in the event that
the other Party breaches a material provision of this Agreement and fails to cure such breach within [      ] of
notice of the breach. 

    13.3  Bankruptcy or Insolvency.  Either Party may, in addition to any other remedies available to it by
law or in equity, terminate this Agreement, upon [  ] written notice to the other Party in the event the other
Party shall have become insolvent or bankrupt, or shall have made an assignment for the benefit of its creditors, or there shall have been appointed a trustee or receiver of the other Party for all or
a substantial part of its property, or any case or proceeding shall have been commenced or other action taken by or against the other Party in bankruptcy or seeking reorganization, liquidation,
dissolution, winding-up, arrangement, composition or readjustment of its debts or any relief under any bankruptcy, insolvency, reorganization or other similar act or law of any
jurisdiction now or hereinafter in effect (an "Insolvency Event"). 

    13.4  Termination Relating to Sales of Competing Products.  SuperGen may, at its sole discretion,
terminate this Agreement with [  ] notice to EuroGen if EuroGen directly or indirectly develops, markets, sells,
or otherwise distributes any products within the Territory which could compete with the Products, or EuroGen appoints any Third Party to develop, market, sell, or otherwise distribute any such
products which could compete with Products during the term of this Agreement. 

    13.5  Effect of Termination.  

    13.5.1  Accrued Rights and Obligations.  Expiration or termination of this Agreement shall not release
any Party from liability accrued under this Agreement prior to such expiration or termination, nor preclude either Party from pursuing any rights or remedies accrued prior to such expiration or
termination or accrued at law or in equity with respect to any breach of this Agreement. It is understood and agreed that monetary damages may not be a sufficient remedy for any breach of this
Agreement and that the non-breaching Party may be entitled to injunctive relief as a remedy for any such breach. 

    13.5.2  Return of Materials.  All trademarks, marks, trade names, data, literature, and sales and
promotional aids of every kind relating to the Products and received from or owned by SuperGen shall remain the property of SuperGen. Neither Party shall make or retain any copies of any Confidential
Information of the other, which may have been entrusted to it. Within thirty (30) days of the expiration or termination of this Agreement under this Article 13, EuroGen shall use its
reasonable efforts to provide SuperGen with a complete inventory of the Product in EuroGen's possession or control. 

    13.6  Phase-Out Period.  Upon expiration or termination of this Agreement under this
Article 13, EuroGen may continue to distribute the Product until the earlier to occur of (i) the sale of all existing Products in EuroGen's possession at the time of termination or
expiration, or (ii) a period of [      ] following the date of
termination or expiration (individually, the "Phase Out Period"), unless such period is terminated earlier in writing by SuperGen. During such Phase-Out Period, EuroGen may continue to
fill all outstanding orders for Products and EuroGen shall refer any new orders for Products to SuperGen. EuroGen shall promptly return all promotional materials for the Products to SuperGen and shall
delete the Products from its catalogues and price lists as soon as reasonably practical. In the event of any problems relating to the Products or customer relations issue during the 

18

 

Phase-Out Period, EuroGen shall cooperate fully with SuperGen to ensure customer satisfaction and compliance with all applicable laws and regulations. 

    13.7  Post-Termination Orders.  After expiration or termination of this Agreement the
placement of any order for Products by EuroGen to SuperGen, and the acceptance of any order from, or sale of any Products to EuroGen by SuperGen, shall not be construed as a renewal or extension of
this Agreement nor as a waiver or reversal of termination of this Agreement. 

    13.8  Survival.  The provisions of Sections 2.8, 2.10, 5.4, 5.6, 6.2 and 10.2, and Articles 1, 9, 11, 12,
13 and 14 shall survive expiration or termination of this Agreement for any reason. Except as otherwise provided in this Article 13, all rights and obligations of the Parties under this
Agreement shall terminate upon expiration or termination of this Agreement for any reason. 

14.  MISCELLANEOUS  

    14.1  Governing Law.  This Agreement and any dispute arising from the performance or breach hereof shall
be governed by and construed and enforced in accordance with, the laws of the State of California, without reference to conflict of laws principles. The United Nations Convention on Contracts for the
International Sale of Goods shall not apply. 

    14.2  Dispute Resolution.  

    14.2.1  Disputes.  If the Parties are unable to resolve any dispute between them arising out of or in
connection with this Agreement, either Party may, by written notice to the other, have such dispute referred to the Chief Executive Officers ("CEO") of each SuperGen and EuroGen for attempted
resolution by good faith negotiations within sixty (60) days after such notice is received, and in such event, each Party shall cause its CEO to meet and be available to attempt to resolve such
issue. 

    14.2.2  Arbitration.  EuroGen and SuperGen agree that any dispute or controversy arising out of, in
relation to, or in connection with this Agreement, or the validity, enforceability, construction, performance or breach hereof, shall be settled by binding arbitration under the then current
Commercial Arbitration Rules of the American Arbitration Association. Any such arbitration shall be conducted in the English language, and the venue of such arbitration shall be the greater San
Francisco and East Bay areas in California, United States. The arbitration shall be conducted by a single arbitrator appointed in accordance with such rules, provided that if either Party requests the
arbitration shall be conducted by a panel of three (3) arbitrators appointed in accordance with such rules. The arbitrator(s) shall determine what discovery will be permitted, based on the
principle of limiting the cost and time which the Parties must expend on discovery; provided that the arbitrator(s) shall permit such discovery as they deem necessary to achieve an equitable
resolution of the dispute. The decision and/or award rendered by the arbitrator(s) shall be written, final and non-appealable and may be entered in any court of competent jurisdiction. The
Parties agree that, any provision of applicable law notwithstanding, they will not request, and the arbitrator shall have no authority to award, punitive or exemplary damages against any Party. The
costs of any arbitration, including administrative fees and fees of the arbitrator(s), shall be shared equally by the Parties, unless otherwise specified by the arbitrator(s). Each Party shall bear
the cost of its own attorneys' and expert fees; provided that the arbitrator(s) may in their discretion award to the prevailing Party the costs and expenses incurred by the prevailing Party in
connection with the arbitration proceeding. 

    14.3  Notices.  Any notice or report required or permitted to be given or made under this Agreement by
either Party shall be in writing and delivered to the other Party at its address indicated below (or to such other address as a Party may specify by notice hereunder) by overnight courier service or
by facsimile; provided, however, that all facsimile notices shall be promptly confirmed, in 

19

 

writing, by overnight courier service. All notices shall be effective as of the date received by the addressee. 

    If
to SuperGen: SuperGen, Inc., 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, Fax:(925) 551-6478, Attention: Dr. Joe Rubinfeld, Chief Executive
Officer and President 

    Copy
to: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050, Fax: 650 493-6811 

    If
to EuroGen:      EuroGen Pharmaceuticals Ltd. The Gloucestershire Innovation Centre, Southgate House, Southgate Street, Gloucester GL1 1UD, England, Fax: 011 44
1452 563 016 Attention: Larry Johnson, President and Managing Director 

    Copy
to: James E. Burden, Inc., One Maritime Plaza, 4th Floor, San Francisco, CA 9411-3407, Fax: 415 433-2996 

    14.4  Binding Effect; Assignment.  Except as otherwise provided herein, this Agreement may not be
assigned, in whole or in part, by either Party without the prior written consent of the other Party, and any attempted assignment without such consent shall be null and void. Notwithstanding the
foregoing, no prior written consent shall be required in the event that a Third Party acquires substantially all of the assets or outstanding shares of, or merges with, the assigning Party, but only
so long as (i) such Third Party agrees to be bound by all of the assigning Party's responsibilities and obligations hereunder and (ii) the other Party has determined, in the exercise of
its reasonable commercial judgment, that the interests of such Third Party are not in conflict with the interests of such other Party with respect to the Product. No assignment of this Agreement or of
any rights hereunder shall relieve the assigning Party of any of its obligations or liability hereunder. This Agreement shall inure to the benefit of and be binding upon each of the Parties hereto and
their respective successors and permitted assigns. 

    14.5  Force Majeure.  If any circumstance beyond the reasonable control of either Party occurs, which,
delays or renders impossible the performance of certain of that Party's obligations under this Agreement on the dates herein provided ("Force Majeure"), such obligations shall be postponed for such
time as such performance necessarily has had to be suspended or delayed on account thereof, provided such Party shall notify the other Party in writing as soon as practicable, but in no event more
than ten (10) business days after the occurrence of such event of Force Majeure, which notice shall reasonably attempt to identify such obligations under this Agreement and the extent to which
performance thereof will be affected. In such event, the Parties shall meet promptly to determine an equitable solution to the effects of any such event, provided that such Party who fails because of
an event of Force Majeure to perform its obligations hereunder shall upon the cessation of the Force Majeure event take all reasonable steps within its power to resume with the least possible delay
compliance with its obligations. Events of Force Majeure shall include, without limitation, war, revolution, invasion. insurrection, riots, mob violence, sabotage, or other civil disorders, acts of
God, limitations imposed by exchange control regulations or foreign investment regulations or similar regulations, laws, regulations or rules of any government or governmental agency, any inordinate
and unanticipated delays in the regulatory review or governmental approval process that are within the sole control of such government or governmental agency, any delay or failure in manufacture,
production or supply by Third Parties of any goods or services, any withdrawal or recall of a Product at the direction of any governmental authority and any failure of a computer system. 

    14.6  Amendment.  This Agreement may be modified, amended or extended only by the written agreement of
the Parties through their duly authorized officers or representatives, specifically referring to this Agreement. 

    14.7  Severability.  If any provision hereof should be held invalid, illegal or unenforceable in any
jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision 

20

 

that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to
carry out the intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision
in any other jurisdiction. 

    14.8  Headings.  The descriptive headings contained in this Agreement are included for convenience of
reference only and shall not affect the meaning or interpretation of this Agreement. 

    14.9  Entire Agreement.  This Agreement and the exhibits hereto represent and constitute the entire
agreement between the parties with respect to the subject matter hereof, and supersedes and merges all prior negotiations, agreements and understandings, oral or written, with respect to the matters
covered by this Agreement. 

    14.10  Conflict of Terms.  In the event of any conflict between the terms and conditions of this
Agreement and any terms and conditions that may be set forth on any order, invoice, verbal agreement or otherwise, the terms and conditions of this Agreement shall govern. Unless otherwise explicitly
stated, in the event of any conflict between the terms of this Agreement and the terms and conditions of any of the Exhibits hereto, the terms of this Agreement shall prevail. 

    14.11  No Waiver of Rights.  No failure or delay on the part of either Party in the exercise of any power
or right hereunder shall operate as a waiver thereof. No single or partial exercise of any right or power hereunder shall operate as a waiver of such right or of any other right or power. The waiver
by either Party of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any other or subsequent breach hereunder. 

    14.12  Counterparts.  The Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, and all of which together shall constitute one instrument. 

IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized officers as of the date first written above. 

	SUPERGEN, INC.	 	EUROGEN PHARMACEUTICALS LTD.
	

By:	
 	

/s/ DR. JOSEPH RUBINFELD   
	
 	

By:	
 	

/s/ LARRY C. JOHNSON   

	Name:	 	Dr. Joseph Rubinfeld
	 	Name:	 	Larry C. Johnson

	Title:	 	President & CEO
	 	Title:	 	President & CEO

EXHIBIT A  

AUTHORIZED SUPERGEN TRADEMARKS, MARKS AND TRADE NAMES  

    [To be provided by SuperGen] 

21

QuickLinks

Exhibit 10.1Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.24    
  

 
  EMPLOYEE LOAN AGREEMENT    
  

    THIS EMPLOYEE LOAN AGREEMENT ("Agreement") is entered into as of the 22nd day of August, 2001, by and between
COMMERCE ONE, INC., a Delaware corporation (the "Company"), and DENNIS H. JONES ("Jones"). 

RECITALS  

    (a) Jones
is employed by the Company as its Vice Chairman and President. 

    (b) Jones
has purchased a residence at 8009 Horizons Court, Pleasanton, California (the "Property" using Two Million Four Hundred Twenty-Five Thousand
Dollars ($2,425,000) borrowed from the Company (the "Bridge Loan"). 

    (c) The
Company and Jones desire that Bank of America, N.A. ("BofA") lend to Jones the sum of up to Three Million Five Hundred Thousand Dollars ($3,500,000.00) to
assist Jones in repaying the Bridge Loan, purchasing the Property and incurring other expenses (the "BofA Loan"). 

    (d) The
Company intends to guaranty the BofA Loan in accordance with the terms of a separate agreement between BofA and the Company (the "Guaranty"). 

    NOW,
THEREFORE, the Company and Jones agree as follows: 

AGREEMENT  

    1.  Payment: BofA will extend to Jones the BofA Loan, which amount shall be used by Jones only
for the purposes of (a) repaying the Bridge Loan, (b) landscaping the Property and making interior improvements, and (c) incurring other related expenses such as purchasing
furniture. 

    2.  Conditions Precedent: The Company's obligation to guaranty the Loan to Jones pursuant to
this Agreement is expressly conditioned upon the satisfaction of or waiver by the Company of all of the following conditions precedent, each of which is exclusively for the benefit of the Company: 

    (a) Jones
shall have delivered to the Company each of the following (herein referred to as "Loan Documents") 

    (1) One
(1) original individual loan agreement in the amount of Three Million Five Hundred Thousand Dollars ($3,500,000.00) in substantially the same form as  Exhibit A attached hereto (the "BofA
Individual Loan Agreement"), with all uncompleted information fully completed; and
 

    (2) One
(1) fully executed "Indemnity Agreement Secured by Deed of Trust" in substantially the same form as Exhibit B  attached hereto (the "Indemnity Agreement"), with all uncompleted information
fully completed; and 

    (3) One
(1) fully executed, validly acknowledged deed of trust and the rider thereto, encumbering the Property as security for the Indemnity Agreement, in
substantially the same form as Exhibit C attached hereto, with all uncompleted information fully completed (the "Deed of Trust"); and 

    (4) One
(1) fully executed "Tax Matters Agreement" in substantially the same form as Exhibit D, with all
uncompleted information fully completed (the "Tax Matters Agreement"). 

    (b) The
Company shall have received from First American Title Guaranty Company (the "Title Company"), a title insurance policy insuring the Deed of Trust in the amount
of $2,425,000 as a first
lien on the Property, subject only to the exceptions to title described in Items Nos.1-4 of that certain Preliminary Report prepared by the Title Company, dated June 7, 2001, and
bearing Order No. 300485, and including the following title insurance endorsements: 100, 103.7, and 110.9. 

 

    3.  Jones' Representations and Warranties: Jones hereby makes the following representations and
warranties to the Company, which representations and warranties shall be true and correct as of the date of the close of escrow for Jones' purchase of the Property, and Jones acknowledges that the
Company is relying on such representations in guarantying the Loan: 

    (a) At
the closing of the BofA Loan and the Guaranty, Jones will have good and marketable title to the Property free and clear of any security interests, liens or
encumbrances securing monetary obligations. 

    (b) The
consent of no other person or entity is required to grant the Company the security interest in the Property evidenced by the Deed of Trust. 

    (c) There
are no actions, proceedings, claims or disputes pending or, to Jones' knowledge, threatened against or affecting Jones, the Property, or any other properties
of Jones. 

    4.  Jones' Additional Obligations: Jones shall take any and all further actions that may from
time to time be required to ensure that the Deed of Trust creates a valid first priority lien on the Property in favor of the Company, which shall secure the Indemnity Agreement. Upon request by
Company, but not more frequently than once during any calendar year unless Company believes in good faith that a title issue exists, Jones shall furnish evidence reasonably satisfactory to the Company
that: (i) Jones has good and marketable title to the Property; (ii) the consent of no other person or entity is required to grant a first priority security interest in the Property to
the Company; (iii) the Deed of Trust is a first priority security interest in the Property, and (iv) there are no other deeds of trust, mortgages or encumbrances against the Property. If
it should be hereafter determined that there are defects against title or matters which could result in defects against title to the Property or that the consent of another person or entity is
required to grant to and perfect in the Company a valid first-priority lien on the Property, Jones shall promptly take all action necessary to remove such defects and to obtain such consent and grant
(or cause to be granted) and perfect such lien on the Property. Failure of the Deed of Trust to be a valid first lien against the Property shall be deemed a Payment Event, as defined in the Indemnity
Agreement. 

    5.  Repayment of Loan: Jones shall timely pay and perform all amounts and other obligations
under all promissory notes and other documents and instruments from time to time evidencing, or securing, the BofA Loan, the Indemnity Agreement and the Deed of Trust, except as expressly provided in
such
documents to the contrary. In particular, but without limitation, Jones shall timely pay to the Company the outstanding principal balance required under the Indemnity Agreement, together with all
accrued, but unpaid interest thereon, and all other sums due hereunder, under the Indemnity Agreement, or under any other document executed by Jones in connection herewith in accordance with the terms
and conditions of this Agreement, the Indemnity Agreement or such other document. 

    6.  Payment Event: Jones expressly agrees that the amounts required under the Indemnity
Agreement and the Tax Matters Agreement shall immediately become due and payable, without notice or demand, upon the occurrence of any "Payment Event" as defined in the Indemnity Agreement. 

    7.  Interest Payable by Jones: Interest shall accrue on the unpaid principal amounts due under
the Indemnity Agreement at the rate specified in the Indemnity Agreement. 

    8.  Entire Agreement: This Agreement, together with the Loan Documents, constitutes the full and
entire understanding and agreement between the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended, waived, discharged, or terminated
other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge, or termination is sought. No waiver of any provision of this Agreement or any
other Loan Document shall be effective unless in writing and the waiver of any one provision shall not be deemed a waiver of any other provision unless expressly stated in writing. All rights and
remedies of the Company described herein and in any other documents or instruments 

2

 

evidencing or securing the loan (including, without limitation, the Loan Documents) shall be cumulative and not restrictive of any other rights or remedies available under any other document or
instrument, at law or in equity. 

    9.  No Covenant for Employment or Advances: Jones understands and acknowledges that this
Agreement does not modify Employee's at-will status at the Company and does not constitute an employment agreement or a promise by the Company to continue Jones' employment. Either the
Company or Jones may terminate such employment relationship at any time, with or without cause. 

    10. Notices: All notices and other communications required or permitted hereunder shall be in
writing and may be given by (a) personal delivery, (b) certified mail, postage prepaid, return-receipt requested, (c) courier service, fully prepaid for next business day
delivery, or (d) facsimile. Any such notice shall be properly addressed to the address of the parties set forth on the signature page hereof and shall be deemed to have been given (i) if
personally delivered, when delivered, (ii) if by certified mail, return-receipt requested, when delivered or refused, (iii) if by courier service, on the next business day following
deposit, cost prepaid, with Federal Express or similar private carrier, or (iv) if by facsimile, instantaneously upon confirmation of receipt of facsimile. The Company or Jones may change their
address by giving notice of the same in accordance with this paragraph. The term "business day" shall mean a day on which national banks are open for business in San Francisco, California. 

    11. Assignment: Jones may not assign any of his rights and/or duties under this Agreement or any
of the other Loan Documents without the prior written consent of the Company, which consent may be withheld in the sole discretion of Company. All of the rights and/or duties of the Company under the
Loan Documents, or any of them, shall be freely assignable. Subject to the foregoing, the rights and obligations of Jones and Company under the Loan Documents shall be binding upon and shall inure to
the benefit of Jones and Company and his respective personal representatives, successors, heirs, and permitted assigns. 

    12. Income Tax Consequences: Jones hereby acknowledges that (except as expressly set forth in
Paragraph 1 of the Tax Matters Agreement) the Company has made no representation or warranty to Jones concerning the income tax consequences of the loan to Jones and Jones shall be solely
responsible for ascertaining and bearing such tax consequences. 

    13. Governing Law: This Agreement shall be governed in all respects by the laws of the State of
California. 

    14. Headings: The titles and headings of the various paragraphs hereof are intended for means of
reference and are not intended to place any construction on the provisions hereof. 

    15. Invalidity: If any provision of this Agreement shall be invalid or unenforceable the
remaining provisions shall not be affected thereby and every provision hereof shall be valid and enforceable to the fullest extent permitted by law. 

    16. Counterparts: This Agreement may be executed in one (1) or more separate
counterparts, each of which, when so executed, shall be deemed to be an original. Such counterparts, together, shall constitute one and the same instrument. 

    17. Miscellaneous: Time is of the essence of this Agreement, the Loan Documents, and any other
document executed by Jones in connection therewith. If any action shall be commenced between the parties with respect to the Loan, or any such documents, the prevailing party shall be entitled to
recover its reasonable attorneys' fees and expenses from the non-prevailing party or parties. Liability hereunder shall be joint and several both between Jones and among all other persons
and entities now or hereafter liable for all or any part of the Loan or any obligations under the Indemnity Agreement or the other Loan Documents. 

3

 

    IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above. 

	JONES:	 	THE COMPANY:
	

/s/ DENNIS H. JONES   
 DENNIS H. JONES	
 	

COMMERCE ONE, INC.,

a Delaware corporation
	

 	
 	

By:	
 	

/s/ MARK B. HOFFMAN   

	 	 	 	 	  

	 	 	Its:	 	Chairman & CEO

	Address:	 	Dennis H. Jones

8009 Horizons Court

Pleasanton, CA 94588	 	Address:	 	Commerce One, Inc.

4440 Rosewood Drive, Bldg. 4

Pleasanton, CA 94588

Attn: James Bryant

	Telephone:	 	( )	 	  
	 	Telephone:	 	( )	 	  

	Facsimile:	 	( )	 	  
	 	Facsimile:	 	( )	 	  

4

  

Exhibit A  

  
 

    FORM OF BOFA INDIVIDUAL LOAN AGREEMENT    
  

    This Agreement dated as of August 22, 2001 is between Bank of America, N.A. (the "Bank") and Dennis H. Jones (the "Borrower"). 

1.  TERM LOAN AMOUNT AND TERMS  

1.1 Loan Amount.  The Bank agrees to provide a term loan to the Borrower in the amount of Three Million Five Hundred
Thousand and 00/100 Dollars ($3,500,000.00) (the "Commitment"). 

1.2 Availability Period.  The loan is available in one disbursement from the Bank between the date of this Agreement and
August 31, 2001 unless the Borrower is in default. 

1.3 Interest Rate.

	(a)
	The
interest rate is a rate per year equal to the Wall Street Journal LIBOR Rate plus 2.00 percentage points.

	(b)
	The
interest rate will be adjusted on the 8th day of every August (the "Adjustment Date") and remain fixed until the next Adjustment Date. If the Adjustment Date in any particular
month would otherwise fall on a day that is not a banking day, the Adjustment Date for that particular month will be the first banking day immediately following thereafter.

	(c)
	The
Wall Street Journal LIBOR Rate is a rate of interest equal to the twelve month London interbank offered rate as published in the "Money Rates" section of The Wall Street Journal
on the banking day immediately preceding the Adjustment Date (or, if such source is not available, such alternate source as determined by the Bank), as adjusted from time to time in the Bank's sole
discretion for reserve requirements, deposit insurance assessment rates and other regulatory costs. 

1.4 Repayment Terms.

	(a)
	The
Borrower will pay all accrued but unpaid interest on the first day of each month and upon payment in full of the principal of this loan.

	(b)
	The
Borrower will repay in full any principal, interest or other outstanding charges on the loan no later than August 7, 2005. 

1.5 Prepayments.

	(a)
	The
Borrower may prepay the loan in full or in part at any time in an amount not less than One Hundred Thousand and 00/100 Dollars ($100,000.00). The Borrower will give the Bank
irrevocable written notice of the Borrower's intention to make the prepayment, specifying the date and amount of the prepayment. The notice must be received by the Bank at least 5 banking days in
advance of the prepayment. The prepayment will be applied to the most remote payment of principal due under this Agreement.

	(b)
	Each
prepayment, whether voluntary, by reason of acceleration or otherwise, will be accompanied by the amount of accrued interest on the amount prepaid, and the prepayment fee
described below.

	(c)
	The
prepayment fee shall be in an amount sufficient to compensate the Bank for any loss, cost or expense incurred by it as a result of the prepayment, including any loss of
anticipated profits and any loss or expense arising from the liquidation or reemployment of funds obtained by it to maintain the loan or from fees payable to terminate the deposits from which such
funds were obtained. The Borrower shall also pay any customary administrative fees charged by the Bank in connection with the foregoing. For purposes of this paragraph, the Bank shall be deemed to
have 

1

 

funded
the loan by a matching deposit or other borrowing in the applicable interbank market, whether or not the loan was in fact so funded. 

2.  FEES AND EXPENSES  

2.1 Fees

	(a)
	Loan fee.  The Borrower agrees to pay a fee equal to 1% of the amount disbursed. This fee is due on the date funds are
advanced under this Agreement.

	(b)
	Waiver Fee.  If the Bank, at its discretion, agrees to waive or amend any terms of this Agreement, the Borrower will,
at the Bank's option, pay the Bank a fee for each waiver or amendment in an amount advised by the Bank at the time the Borrower requests the waiver or amendment. Nothing in this paragraph shall imply
that the Bank is obligated to agree to any waiver or amendment requested by the Borrower. The Bank may impose additional requirements as a condition to any waiver or amendment.

	(c)
	Late Fee.  To the extent permitted by law, the Borrower agrees to pay a late fee in an amount not to exceed four
percent (4%) of any installment that is more than fifteen (15) days late. The imposition and payment of a late fee shall not constitute a waiver of the Bank's rights with respect to the default. 

2.2 Reimbursement Costs.

	(a)
	The
Borrower agrees to reimburse the Bank for any expenses it incurs in the preparation of this Agreement and any agreement or instrument required by this Agreement. Expenses
include, but are not limited to, reasonable attorneys' fees, including any allocated costs of the Bank's in-house counsel.

	(b)
	The
Borrower agrees to reimburse the Bank for the cost of periodic audits and appraisals of the personal property collateral securing this Agreement, at such intervals as the Bank
may reasonably require. The audits and appraisals may be performed by employees of the Bank or by independent appraisers. 

3.  COLLATERAL  

3.1 Lent Collateral.  The Borrower's obligations to the Bank under this Agreement will be secured by personal property now
owned or owned in the future by Commerce One, Inc. as listed below. The collateral is further defined in security agreement(s) executed by Commerce One, Inc. 

	(a)
	Bank
of America, N.A. time deposits in an amount not less than Three Million Five Hundred Thousand Dollars ($3,500,000). 

4.  DISBURSEMENTS, PAYMENTS AND COSTS  

4.1 Direct Debit.

	(a)
	The
Bank shall debit Commerce One, Inc.'s designated deposit account with the Depository listed below (the "Designated Account") in the amount of each payment of principal,
interest and other fees and charges under this Agreement on the date such payments become due. 

	 
	 
	 	 

	 	Depository Name:	 	Commerce One, Inc.
	 	Address:	 	Bank of America

Dallas, TX75762
	 	Routing Number:	 	111-000-012
	 	Commerce One Inc.'s Deposit Account Number:  375-161-7419
	 	(A voided copy of a check on this account is attached to this Agreement).

2

 
	(b)
	Commerce
One, Inc. authorizes the Bank to debit the Designated Account by no later than the close of business on the dates payments become due. The ACH debits shall be subject to
the operating rules of the National Automated Clearing House Association, as in effect from time to time.

	(c)
	Commerce
One, Inc. shall maintain sufficient funds in the Designated Account on the dates the Bank enters debits authorized by this Agreement. If there are insufficient funds in the
Designated Account on the date the Bank enters any debit authorized by this Agreement, such debit will be reversed.

	(d)
	The
Bank or Commerce One, Inc. may terminate this direct debit arrangement at any time by notice in writing to the other party. Any such termination notice shall be effective ten
(10) days after its receipt; provided, however, that at the Bank's discretion, any such termination notice shall be effective immediately upon any default under this Agreement or for other reasonable
cause. In the event the Bank or Commerce One, Inc. terminates this direct debit arrangement, Commerce one, Inc. shall commence, as of the date such termination is effective, to make
principal, interest and other payments in the funds and at such office of the Bank as the Bank may from time to time select or as otherwise provided in any agreement between the Bank and the Borrower.

	(e)
	The
Bank will initiate debits on the dates the payments become due. If a due date does not fall on a banking day, the Bank will initiate debits on the first banking day following
the due date. 

4.2 Banking Days.  Unless otherwise provided in this Agreement, a banking day is a day other than a Saturday or a Sunday
on which the Bank is open for business in California. For amounts bearing interest at an offshore rate (if any), a banking day is a day other than a Saturday or a Sunday on which the Bank is open for
business in California and dealing in offshore dollars. All payments and disbursements which would be due on a day which is not a banking day will be due on the next banking day. All payments received
on a day which is not a banking day will be applied to the credit on the next banking day. 

4.3 Interest Calculation.  Except as otherwise stated in this Agreement, all interest and fees, if any, will be computed
on the basis of a 360-day year and the actual number of days elapsed. This results in more interest or a higher fee than if a 365-day year is used. Installments of principal which are not paid when
due under this Agreement shall continue to bear interest until paid. 

4.4 Default Rate.  Upon the occurrence of any default under this Agreement, principal amounts outstanding under this
Agreement will at the option of the Bank bear interest at a rate which is 4 percentage point(s) higher than the rate of interest otherwise provided under this Agreement. This will not constitute a
waiver of any default. 

5.  CONDITIONS  

The
Bank must receive any documents and other items it may reasonably require, including but not limited to the following items, in form and content acceptable to the Bank, before it is required to
extend any credit to the Borrower under this Agreement. 

5.1 Authorizations.  Evidence that the execution, delivery and performance by each guarantor of this Agreement and any
instrument or agreement required under this Agreement have been duty authorized. 

5.2 Security Agreements.  Signed optional security agreements, assignments, financing statements and fixture filings
(together with collateral in which the Bank requires a possessory security interest), which the Bank requires. 

5.3 Evidence of Priority.  Evidence that security interests and liens in favor of the Bank are valid, enforceable, and
prior to all others' rights and interests, except those the Bank consents to in writing. 

3

 

5.4 Guaranty.  A guaranty signed by Commerce One, Inc. in the amount of Three Million Five Hundred Thousand Dollars
($3,500,000). 

6.  REPRESENTATIONS AND WARRANTIES  

When
the Borrower signs this Agreement, and until the Bank is repaid in full, the Borrower makes the following representations and warranties. Each request for an extension of credit constitutes a
renewed representation. 

6.1 Lawsuits.  There is no lawsuit, tax claim or other dispute pending or threatened against the Borrower which, if lost,
would impair the Borrower's financial condition or ability to repay the loan, except as have been disclosed in writing to the Bank. 

6.2 Location of Borrower.  The Borrower is located at the address listed under the Borrower's signature on this Agreement.
For the purpose of this paragraph, the Borrower's location is one of the following: 

	(a)
	the
Borrower's place of business, if there is one; or

	(b)
	if
the Borrower has more than one place of business, its chief executive office; or

	(c)
	if
the Borrower has no place of business, the Borrower's residence. 

7.  COVENANTS  

The
Borrower agrees, so long as credit is available under this Agreement and until the Bank is repaid in full: 

7.1 Use of Proceeds.  To use the proceeds of the credit only for financing the purchase, landscaping, and furnishings of a
new residence in Pleasanton, California. 

7.2 Notice to Bank.  To promptly notify the Bank in writing of: 

	(a)
	any
lawsuit over One Hundred Thousand Dollars ($100,000) against the Borrower (or any guarantor) or any trustor or any of the Borrower's property or business,

	(b)
	any
substantial dispute between the Borrower (or any guarantor) or any trustor and any government authority, or which may affect the Borrower's property or business,

	(c)
	any
event of default under this Agreement, or any event which, with notice or lapse of time or both, would constitute an event of default,

	(d)
	any
material adverse change in the Borrower's (or any guarantor's) or any trustor's business condition (financial or otherwise), operations, properties or prospects, or ability to
repay the credit,

	(e)
	any
change in the Borrower's name or address,

	(f)
	any
actual contingent liabilities of the Borrower (or any guarantor), and any such contingent liabilities which are reasonably foreseeable. 

7.3 Inspections and Appraisals.  To allow the Bank and its agents to inspect and appraise any of the collateral securing
this Agreement and examine, audit and make copies of books and records concerning the collateral at any reasonable time. If any of the collateral, books or records are in the possession of a third
party, the Borrower authorizes that third party to permit the Bank or its agents to have access to perform inspections, appraisals or audits. 

7.4 Compliance with Laws.  To comply with the laws, regulations, and orders of any government body with authority over the
Borrower's business. 

4

 

7.5 Perfection of Liens.  To help the Bank perfect and protect its security interests and liens, and reimburse it for
related costs it incurs to protect its security interests and liens. 

7.6 Insurance.  To maintain insurance as is usual for the business it is in. 

7.7 Additional Negative Covenants.  Not to, without the Bank's written consent: 

	(a)
	engage
in any business activities substantially different from the Borrower's present business,

	(b)
	acquire
or purchase a business or its assets. 

8.  DEFAULT  

If
any of the following events occurs, the Bank may do one or more of the following: declare the Borrower in default, stop making any additional credit available to the Borrower, and require the
Borrower to repay its entire debt immediately and without prior notice. If an event of default occurs under the paragraph entitled "Bankruptcy," below, with respect to the Borrower, then the entire
debt outstanding under this Agreement will automatically be due immediately. 

8.1 Failure to Pay.  The Borrower fails to make a payment under this Agreement within 5 days after the date when
due. 

8.2 Lien Priority.  The Bank fails to have an enforceable first lien (except for any prior liens to which the Bank has
consented in writing) on or security interest in any property given as security for this Agreement (or any guaranty). 

8.3 False Information.  The Borrower (or any guarantor) has given the Bank false or misleading information or
representations. 

8.4 Death.  The Borrower dies or becomes legally incompetent. 

8.5 Bankruptcy.  The Borrower (or any guarantor) files a bankruptcy petition, a bankruptcy petition is filed against the
Borrower (or any guarantor) or the Borrower (or any guarantor) makes a general assignment for the benefit of creditors. 

8.6 Receivers.  A receiver or similar official is appointed for a substantial portion of the Borrower's (or any
guarantor's) business, or the business is terminated, or any guarantor is liquidated or dissolved. 

8.7 Judgments.  Any judgments or arbitration awards are entered against the Borrower (or any guarantor), or the Borrower
(or any guarantor) enters into any settlement agreements with respect to any litigation or arbitration, in an aggregate amount of Two Hundred Fifty Thousand Dollars ($250,000) or more in excess of any
insurance coverage. 

8.8 Government Action.  Any government authority takes action that the Bank believes materially adversely affects the
Borrower's (or any guarantor's) financial condition or ability to repay. 

8.9 Material Adverse Change.  A material adverse change occurs, or is reasonably likely to occur, in the Borrower's (or
any guarantor's) business condition (financial or otherwise), operations, properties or prospects, or ability to repay the credit. 

8.10 Cross-default.  Any default occurs under any agreement in connection with any credit the Borrower (or any guarantor)
has obtained from anyone else or which the Borrower (or any guarantor) has guaranteed. 

8.11 Default under Related Documents.  Any guaranty, subordination agreement, security agreement, deed or trust, or other
document required by this Agreement is violated or no longer in effect. If, in the Bank's opinion, the breach is capable of being remedied, the breach will not be considered an event of default under
this Agreement for a period of five (5) days after the date on which the Bank 

5

 

gives written notice of the breach to the Borrower, provided, however, that the Bank will not be obligated to extend any additional credit to the Borrower during that period. 

8.12 Other Bank Agreements.  The Borrower (or any guarantor) fails to meet the conditions of, or fails to perform any
obligation under any other agreement the Borrower (or any guarantor) has with the Bank or any affiliate of the Bank. If, in the Bank's opinion, the breach is capable of being remedied, the breach will
not be considered an event of default under this Agreement for a period of five (5) days after the date on which the Bank gives written notice of the breach to the Borrower, provided, however,
that the Bank will not be obligated to extend any additional credit to the Borrower during that period. 

8.13 Other Breach Under Agreement.  The Borrower fails to meet the conditions of, or fails to perform any obligation
under, any term of this Agreement not specifically referred to in this Article. This includes any failure or anticipated failure by the Borrower to comply with any financial covenants set forth in
this Agreement, whether such failure is evidenced by financial statements delivered to the Bank or is otherwise known to the Borrower or the Bank. If, in the Bank's opinion, the breach is capable of
being remedied, the breach will not be considered an event of default under this Agreement for a period of five (5) days after the date on which the Bank gives written notice of the breach to the
Borrower, provided, however, that the Bank will not be obligated to extend any additional credit to the Borrower during that period. 

9.  ENFORCING THIS AGREEMENT; MISCELLANEOUS  

9.1 Financial Computations.  Except as otherwise stated in this Agreement, all financial information provided to the Bank
and all financial covenants will be made in accordance with accounting principles applied consistently with those applied in the preparation of the Borrower's financial statements dated
July 21, 2001, and shall specifically exclude any upward revaluation of assets (other than marketable securities) after that date. 

9.2 California Law.  This Agreement is governed by California law. 

9.3 Successors and Assigns.  This Agreement is binding on the Borrower's and the Bank's successors and assignees. The
Borrower agrees that it may not assign this Agreement without the Bank's prior consent. 

9.4 Arbitration.  Any claim or controversy ("Claim") between the parties, whether arising in contract or tort or by
statute, resulting from or relating to this Agreement shall, upon the request of either party, be resolved by arbitration in accordance with the Federal Arbitration Act (Title 9, US Code).
Arbitration proceedings will be conducted in accordance with the rules for arbitration of financial services disputes of J.A.M.S./Endispute. The arbitration shall be conducted in any U.S. state where
real or tangible personal property collateral for the credit is located or if there is no such collateral, in California. The arbitration hearing shall commence within ninety (90) days of the
demand for arbitration and close within ninety (90) days of commencement, and any award, which may include legal fees, shall be issued (with a brief written statement of the reasons therefore)
within thirty (30) days of the close of hearing. Any dispute concerning whether a claim is arbitrable or barred by the statute of limitations shall be determined by the arbitrator. This
arbitration provision is not intended to limit the right of any party to exercise self-help remedies, to seek and obtain interim or provisional relief of any kind or to initiate judicial or
non-judicial foreclosure against any real or personal property collateral. 

9.5 Severability; Waivers.  If any part of this Agreement is not enforceable, the rest of the Agreement may be enforced.
The Bank retains all rights, even if it makes a loan after default. If the Bank waives a default, it may enforce a later default. Any consent or waiver under this Agreement must be in writing. 

6

 

9.6 Attorneys' Fees.  The Borrower shall reimburse the Bank for any reasonable costs and attorneys' fees incurred by the
Bank in connection with the enforcement or preservation of any rights or remedies under this Agreement and any other documents executed in connection with this Agreement, and in connection with any
amendment, waiver, "workout" or restructuring under this Agreement. In the event of a lawsuit or arbitration proceeding, the prevailing party is entitled to recover costs and reasonable attorneys'
fees incurred in connection with the lawsuit or arbitration proceeding, as determined by the court or arbitrator. In the event that any case is commenced by or against the Borrower under the
Bankruptcy Code (Title 11, United States Code) or any similar or successor statute, the Bank is entitled to recover costs and reasonable attorneys' fees incurred by the Bank related to the
preservation, protection, or enforcement of any rights of the Bank in such a case. As used in this paragraph, "attorneys' fees" includes the allocated costs of the Bank's in-house counsel. 

9.7 One Agreement.  This agreement and any related security or other agreements required by this Agreement, collectively: 

	(a)
	represent
the sum of the understandings and agreements between the Bank and the Borrower concerning this credit;

	(b)
	replace
any prior oral or written agreement between the Bank and the Borrower concerning this credit; and

	(c)
	are
intended by the Bank and the Borrower as the final, complete and exclusive statement of the terms agreed to by them. 

In
the event of any conflict between this Agreement and any other agreements required by this Agreement, this Agreement will prevail. 

9.8 Indemnification.  The Borrower will indemnify and hold the Bank harmless from any loss, liability, damages, judgments,
and costs of any kind relating to or arising directly or indirectly out of (a) this Agreement or any document required thereunder, (b) any credit extended or committed by the Bank to the
Borrower hereunder, and (c) any litigation or proceeding related to or arising out of this Agreement, any such document, or any such credit. This indemnity includes but is not limited to
attorneys' fees (including the allocated cost of in-house counsel). This indemnity extends to the Bank, its parent, subsidiaries and all of their directors, officers, employees, agents, successors,
attorneys, and assigns. This indemnity will survive repayment of the Borrower's obligations to the Bank. All sums due to the Bank hereunder shall be obligations of the Borrower, due and payable
immediately without demand. 

This
Agreement is executed as of the date stated at the top of the first page. 

Bank of America, N.A.  

	 
	 	 

	/s/ ELLEN B. LEVINE   
	 	/s/ DENNIS H. JONES   

	By: Ellen B. Levine, Senior Vice President	 	Dennis H. Jones
	

Address where notices to the Bank are to be sent:	
 	

Address for Notices:
	

The Private Bank — San Francisco #01329

555 California Street

San Francisco, CA 94111	
 	

c/o Commerce One, Inc.

4440 Rosewood Drive

Pleasanton, CA 94588

7

 

The undersigned acknowledges the provisions of Paragraph 4.1 of this Agreement and agrees that the account shown therein may be debited as set forth therein. The undersigned is the owner of the
account. 

Commerce One, Inc.  

	

/s/ RENE FELICE	
 	

 
	
 Rene Felice
 Treasurer	 	 
	

/s/ MARK B. HOFFMAN	
 	

 
	
 Mark B. Hoffman
 Chairman and CEO	 	 

8

 
 

Exhibit B    
  

 
  INDEMNITY AGREEMENT
  SECURED BY DEED OF TRUST    
  

    THIS INDEMNITY AGREEMENT SECURED BY DEED OF TRUST ("Agreement") is entered into as of the 22nd day of August,
2001, by and between COMMERCE ONE, INC., a Delaware corporation (the "Company"), and DENNIS H. JONES ("Jones"). 

RECITALS  

    A.  Jones
is employed by the Company as its Vice Chairman and President. 

    B.  Jones
has purchased a residence at 8009 Horizons Court, Pleasanton, California (the "Property") using Two Million Four Hundred Twenty-five Thousand
Dollars ($2,425,000) borrowed from the Company (the "Bridge Loan"). 

    C.  The
Company and Jones desire that Bank of America, N.A. ("BofA") lend to Jones the sum of up to Three Million Five Hundred Thousand Dollars ($3,500,000.00) to
assist Jones in three distinct ways: (i) repaying the Bridge Loan (which portion is referred to herein as the "Real Estate Loan"), (ii) landscaping the Property and making interior
improvements (the "Improvement Loan") and (iii) incurring other expenses (the "Supplemental Loan") (all together herein the "BofA Loan"), and bearing an initial interest rate of not more than
LIBOR plus two percent (2%). 

    D.  The
Company has agreed to guaranty the BofA Loan in accordance with the terms of a separate agreement between BofA and the Company (the "Guaranty"), on condition
that Jones execute and deliver to the Company this Agreement, the Deed of Trust (as hereinafter defined), and such other
documents and instruments as the Company may from time to time require to evidence and secure the obligations of Jones under this Agreement (this Agreement, such Deed of Trust, and all such other
documents and instruments being referred to herein collectively as the "Loan Documents"). 

AGREEMENT  

    1.  BofA Loan Documents:  All documents and instruments evidencing or securing
the BofA Loan (the "BofA Loan Documents") shall be in form and substance satisfactory to the Company. Jones shall not execute or deliver any BofA Loan Documents without the prior written consent of
the Company, in the Company's sole and absolute discretion. In particular, but without limitation, the promissory note or loan agreement (the "BofA Note") evidencing the BofA Loan shall be in a
principal amount not exceeding $3,500,000, the rate of interest accruing on the principal amount of the BofA Note shall not exceed LIBOR plus two percent (2%) per annum, the BofA Note shall mature not
more than four (4) years from the date thereof, and the BofA Loan shall not provide for any additional advances of principal to Jones thereunder. After Jones has executed and delivered BofA
Loan Documents approved by the Company, as hereinabove provided, the BofA Loan Documents shall not be amended or modified in any respect, nor shall any term or condition thereof be waived, nor shall
any consent be granted thereunder, without in each instance first having obtained the prior written consent of the Company, in the Company's sole and absolute discretion. Each of the BofA Loan
Documents shall expressly incorporate the provisions of this paragraph. 

    2.  Performance by Jones:  Jones shall pay and perform in a timely manner all
amounts and obligations of Jones under the BofA Loan Documents or otherwise in connection with the BofA loan. Notwithstanding the foregoing sentence, on condition that (i) Jones has otherwise
paid and performed all obligations under the BofA Loan Documents and otherwise in connection with the BofA Loan, (ii) Jones has timely paid and performed all obligations under this Agreement,
the Deed of Trust (as hereinafter defined), the Employee Loan Agreement dated the date hereof between Jones and the Company, and all other documents and instruments from time to time executed and
delivered by Jones to the Company in connection with Jones' obligations under this Agreement (collectively, the "Company Loan Documents"), and (iii) no Payment Event (as hereinafter defined)
has occurred hereunder, the Company shall pay BofA for the account of Jones the regularly-scheduled payments of 

 

interest only required under the BofA Note ("Regular Interest"). Upon the occurrence, however, of any of the events described in the foregoing clauses (i), (ii), or (iii), the Company shall thereafter
have no obligation to make any payments of Regular Interest, and Jones shall be solely responsible for payment of all Regular Interest. 

    3.  Indemnity:  Jones acknowledges that the Company is executing and delivering
the Guaranty as an accommodation only to Jones to facilitate Jones' borrowing of the BofA Loan. Except as provided herein, Jones shall indemnity, defend (with counsel reasonably satisfactory to the
Company), protect and hold harmless the Company from and against any and all Losses (including reasonable attorneys' fees and expenses) arising from or relating in any manner to the BofA Loan and/or
the Property. In particular, but without limitation, Jones shall, immediately upon demand, repay and reimburse the Company any and all amounts from time to time paid by the Company under the Guaranty,
including, without limitation, all principal, interest (excepting only Regular Interest for which the Company is responsible under Paragraph 2), late charges, and other costs from time to time
incurred by the Company under the Guaranty and/or the BofA Loan Documents. All such amounts from time to time paid by the Company under the Guaranty and/or the BofA Loan Documents shall bear interest,
from the date(s) of advance thereof until repaid in full, at the lesser of twelve percent (12%) per annum or the maximum amount permitted by law. All repayments and reimbursements required to be made
hereunder shall be made by Jones free and clear of, and without deduction for, any and all present and future taxes, levies, charges, deductions and withholdings. Jones shall pay upon demand any stamp
or other taxes, levies or charges of any jurisdiction with respect to the execution, delivery, performance and enforcement of this Agreement. 

    4.  Payment Event:  Upon the occurrence of any Payment Event (as hereinafter
defined), Jones shall, immediately at Jones' sole cost and without any demand or notice whatsoever, either (i) pay and satisfy in full the entire outstanding amount of the BofA Loan, including
all principal, interest, and other amounts due thereunder, and cause the full and final release and termination of the Guaranty and the return to the Company of any and all collateral securing the
Company's performance of the Guaranty, (ii) substitute such collateral, provide such substitute guarantors, and take such other actions as may be required by BofA and thereby obtain the full
and final release and termination of the Guaranty and the return to the Company of any and all collateral securing the Company's performance of the Guaranty, or (iii) convey the Property to the
Company by grant deed subject only to those exceptions to title to which the deed of trust is subject (with such conveyance of the Property releasing Jones from any indemnity for Company claims
related to impaired market value caused by market factors), and repay the amount of the Supplemental Loan. 

    5.  Security:  

    (a)  The Real Estate Loan.  The obligations of Jones as to the Real Estate Loan and the Improvement Loan
are secured by that certain Deed of Trust (the "Deed of Trust") of even date herewith made by Jones, as trustor, to First American Title Insurance Company, as trustee, for the benefit of the Company,
as beneficiary, which shall be recorded in the Official Records of the County of Alameda, State of California, encumbering certain real property commonly known as 8009 Horizons Court in the City of
Pleasanton, County of Alameda, State of California (the "Property"), described with particularity in the Deed of Trust, which Jones intends to occupy as his principal place of residence. The Deed of
Trust provides, among other things, as follows: 

"If
the Trustor shall sell, convey, encumber, grant any lien upon, or otherwise alienate the Property, or any part thereof, or any interest therein, or shall be divested of their respective title or
any interest therein in any manner or way, whether voluntarily or involuntarily, without the written consent of the Beneficiary being first had and obtained, in Beneficiary's sole and absolute
discretion, Beneficiary shall
have the right, at its option, except as prohibited by law, to declare an immediate "Payment Event" under the Indemnity Agreement." 

2

 

    (b)  The Supplemental Loan.  Jones agrees to provide such other documents and instruments as the Company
may request to document and collateralize the Supplemental Loan. 

    6.  Payment Event:  To the extent permitted by law, any of the following events
shall be a "Payment Event" under this Agreement, the Deed of Trust, and all other Company Loan Documents: 

    (a)  The
occurrence of the earlier of the maturity date of the BofA Note or the fourth (4th) anniversary of the date of this Agreement. 

    (b)  The
occurrence of any breach or default in the performance of any obligation of Jones contained in this Agreement, the Deed of Trust, any of the other Company Loan
Documents, or any other agreement now or hereafter entered into by Jones, on the one hand, and the Company, on the other hand, with respect to the Property (including, without limitation, any failure
of Jones to repay, reimburse, indemnify and hold harmless the Company as provided in Paragraph 3). 

    (c)  The
occurrence of any breach or default in the performance of any obligation of Jones in any other deed of trust or other security instrument now or hereafter
encumbering the Property. 

    (d)  Jones
shall sell, convey, encumber, grant any lien upon, or otherwise alienate the Property, or any part thereof, or any interest therein, or shall be divested of
his respective title or any interest therein in any manner or way, whether voluntarily or involuntarily, without the written consent of the Company being first had and obtained, in the Company's sole
and absolute discretion. 

    (e)  Any
representation or warranty of Jones contained herein or any other Company Loan Document or in any certificate or agreement entered into by Jones for the
benefit of the Company in connection herewith shall be false or misleading in any material respect. 

    (f)  Jones
(i) admits in writing his inability to pay debts, (ii) make an assignment for the benefit of creditors, (iii) file a voluntary
petition in bankruptcy, effect a plan or other arrangement with creditors, liquidate his assets under arrangement with creditors, or liquidate his assets under court supervision,
(iv) have an involuntary petition in bankruptcy or receivership filed against him that is not discharged within sixty (60) days after such petition is filed, or (v) apply for or
permit the appointment of a receiver or trustee or custodian for any of his property or assets. 

    (g)  Any
involuntary lien, attachment or other encumbrance is imposed against the Property and is not discharged within ten (10) days. 

    (h)  The
Deed of Trust is not promptly recorded against the Property or at any time ceases to be a valid first priority lien on the Property. 

    (i)  The
occurrence of the ninetieth (90th) day following the termination of Jones' employment with the Company for any reason, provided that, if such termination is
due to Jones' death, the Company shall not enforce its rights so long as Jones' heirs, executors, or trustees shall fully cooperate with the Company in listing the Property for sale to provide for the
repayment of the BofA Loan. 

    7.  Jones' Representations:  Jones hereby makes the following representations and
warranties to the Company and acknowledges that the Company is relying on such representations in making the loan: 

    (a)  Jones
shall at all times have good and marketable title to the Property free and clear of any security interests, liens or encumbrances other than the Deed of
Trust in favor of the Company securing this Note. 

    (b)  Each
of the BofA Loan Documents and the Company Loan Documents has been duly executed and delivered by Jones and constitute the legal, valid and binding
obligations of Jones enforceable against Jones in accordance with their respective terms. The consent of no other 

3

 

person or entity is required to execute, deliver and perform the BofA Loan Documents or the Company Loan Documents or to grant to the Company the security interest in the Property evidenced by the
Deed of Trust. 

    (c)  There
are no actions, proceedings, claims, or disputes pending or, to Jones' knowledge, threatened against or affecting Jones or the Property. 

    8.  Jones' Additional Obligations:  Jones shall take any and all further actions
that may from time to time be required to ensure that the Deed of Trust creates a valid first priority lien on the Property in favor of the Company as security as provided herein. Upon request by the
Company, but not more frequently than once during any calendar year, Jones shall furnish evidence reasonably satisfactory to the Company that: (i) Jones' has good and marketable title to the
Property free and clear of any liens or encumbrances other than the Deed of Trust and those matters shown in the title insurance policy issued in favor of the Company and insuring the Deed of Trust as
of the close of escrow of Jones' purchase of the Property; (ii) the consent of no other person or entity is required to grant a first priority security interest in the Property to the Company;
(iii) the Deed of Trust is a first priority security interest in the Property, and (iv) there are no other deeds of trust, mortgages or encumbrances against the Property. If it should be
hereafter determined that there are defects against title or matters which could result in defects against title to the Property, or that the consent of another person or entity is required to grant
to and perfect in the Company a valid first-priority lien on the Property, Jones shall promptly take all action necessary to remove such defects and to obtain such consent and grant (or cause to be
granted) and perfect such lien on the Property. Failure of the Deed of Trust to be a valid first lien against the Property shall be deemed a Payment Event as aforesaid. 

    9.  Distribution of BofA Loan Proceeds:  Jones covenants and warrants that the
proceeds of the BofA loan not used for repaying the Bridge Loan shall be maintained in an insured bank account, and shall not be spent without the prior written consent of the Company, and shall be
promptly documented upon disbursement. 

    10.  Attorneys' Fees:  In the event of Jones' default or the occurrence of any
Payment Event hereunder Jones shall pay all costs of collection, including reasonable attorneys' fees incurred by the holder hereof on account of such collection, whether or not suit is filed hereon. 

    11.  Waiver:  The waiver by the Company of any breach of or default under any
term, covenant or condition contained herein or in any other agreement referred to above shall not be deemed to be a waiver of any subsequent breach of or default under the same or any other such
term, covenant or condition. 

    12.  No Usury:  Anything in this Agreement to the contrary notwithstanding, it is
expressly stipulated and agreed that the intent of Jones and the Company is to comply at all times with all usury and other laws relating to this Agreement. If the laws of the State of California
would now or hereafter render usurious, or are revised, repealed or judicially interpreted so as to render usurious, any amount called for under this Agreement, or contracted for, charged or received
with respect to this Agreement, or if any prepayment by Jones results in Jones having paid any interest in excess of that permitted by law, then it is Jones' and the Company's express intent that all
excess amounts theretofore collected by the Company be refunded to Jones, and the provisions of this Agreement immediately be deemed reformed and the amounts therefor collectible hereunder reduced,
without the necessity of execution of any new document, so as to comply with the then applicable law, but so as to permit the recovery of the fullest amount otherwise called for hereunder. 

    13.  General Provisions:  This Agreement shall be governed by and construed in
accordance with the laws of the State of California. To the extent applicable, Jones hereby waives presentment for payment, protest and demand, notice of protest, demand and dishonor and nonpayment,
and consent that the Company may extend the time for payment or otherwise modify the terms of payment or any 

4

 

part of the whole of the debts created by this Agreement, at the request of any person liable hereon, and such consent shall not alter or diminish the liability of any person. Jones hereby waives the
defense of the statute of limitations in any action on this Note to the extent permitted by law. Time is of the essence of this Agreement, the Deed of Trust and any other document executed by Jones in
connection therewith. Liability hereunder shall be joint and several both between Jones and among all other persons and entities now or hereafter liable for all or any part of this Agreement. 

    14.  Notices:  All notices and other communications required or permitted
hereunder shall be in writing and may be given by (a) personal delivery, (b) certified mail, postage prepaid, return-receipt requested, (c) courier service, fully prepaid for next
business day delivery, or (d) facsimile. Any such notice shall be properly addressed to the address of the parties set forth on the signature page hereof and shall be deemed to have been given
(i) if personally delivered, when delivered, (ii) if by certified mail, return-receipt requested, when delivered or refused, (iii) if by courier service, on the next business day
following deposit, cost prepaid, with Federal Express or similar private carrier, or (iv) if by facsimile, instantaneously upon confirmation of receipt of facsimile. The Company or Jones may
change their address by giving notice of the same in accordance with this paragraph. The term "business day" shall mean a day on which national banks are open for business in San Francisco,
California. 

    15.  Acknowledgement by Jones:  THIS AGREEMENT, THE LOAN AGREEMENT, THE DEED OF
TRUST, ALL OTHER COMPANY LOAN DOCUMENTS, AND ALL RELATED DOCUMENTATION ARE EXECUTED VOLUNTARILY AND WITHOUT ANY DURESS OR UNDUE INFLUENCE ON THE PART OF OR ON BEHALF OF THE PARTIES HERETO, WITH THE
FULL INTENT OF CREATING THE OBLIGATIONS AND SECURITY INTERESTS DESCRIBED HEREIN AND THEREIN. THE PARTIES ACKNOWLEDGE THAT: (a) THEY HAVE READ SUCH DOCUMENTATION; (b) THEY HAVE BEEN
REPRESENTED IN THE PREPARATION, NEGOTIATION AND EXECUTION OF SUCH DOCUMENTATION BY LEGAL COUNSEL OF THEIR OWN CHOICE; (c) THEY UNDERSTAND THE TERMS AND CONSEQUENCES OF THIS AGREEMENT, THE
EMPLOYEE LOAN AGREEMENT, THE DEED OF TRUST, AND ALL RELATED AGREEMENTS AND DOCUMENTATION AND THE OBLIGATIONS THEY CREATE; AND (d) THEY ARE FULLY AWARE OF THE LEGAL AND BINDING EFFECT THEREOF. 

    IN
WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written. 

	/s/ DENNIS H. JONES   
 DENNIS H. JONES	 	COMMERCE ONE, INC.,

a Delaware corporation
	

 	
 	

By:	
 	

/s/ MARK B. HOFFMAN   

	

 	
 	

Its:	
 	

Chairman & CEO

5

Exhibit C  

 
 

Exhibit D    
  

 
  TAX MATTERS AGREEMENT    
  

    THIS TAX MATTERS AGREEMENT ("Agreement") is entered into as of the 22nd day of August, 2001, by and between
COMMERCE ONE, INC., a Delaware corporation (the "Company"), and DENNIS H. JONES ("Jones"). 

RECITALS  

    A.  Jones
is employed by the Company as its Vice Chairman and President. 

    B.  Jones
has purchased a residence in Pleasanton, California (the "Property") using Two Million Four Hundred Twenty-Five Thousand Dollars ($2,425,000)
borrowed from the Company (the "Bridge Loan"). 

    C.  The
Company and Jones desire that Bank of America, N.A. ("BofA") lend to Jones the sum of up to Three Million Five Hundred Thousand Dollars ($3,500,000.00) to
assist Jones in: (i) repaying the Bridge Loan (which portion is referred to herein as the "Real Estate Loan"), and (ii) paying other expenses (together, the "BofA Loan"). 

    D.  The
Company has agreed to guaranty the BofA Loan in accordance with the terms of a separate agreement between BofA and the Company (the "Guaranty"). 

    E.  Jones'
has agreed to indemnify the Company against claims under or related to the Property and the Guaranty, pursuant to that certain Indemnity Agreement Secured By
Deed of Trust of even date herewith (the "Indemnity Agreement") which agreement is incorporated herein by reference as if set out in its entirety. Capitalized terms not defined herein shall have the
meanings given them in the Indemnity Agreement. Pursuant to the Indemnity Agreement, and in pertinent part, prior to the occurrence of a "Payment Event", as defined and herein, the Company has agreed
to make regularly scheduled payments of interest under the BofA Loan. 

AGREEMENT  

    1.  Tax Payments: The Company's payments of regular interest under the BofA Loan may constitute
taxable income to Jones under federal and state law (the resulting tax liability being referred to herein as "Taxes"). Prior to the occurrence of a Payment Event, and otherwise for so long as the
Company is obligated to makes regular payments of interest to BofA under the Indemnity Agreement, including the Company shall advance to Jones such funds as the Company reasonably calculates are
necessary to pay such Taxes. The Company reserves the right to change the amount of such advance at any time in its sole discretion. Jones agrees to provide such documentation and financial
information as the Company shall request in connection herewith. Except as expressly agreed in this Paragraph, the Company shall have no obligation for any taxes of Jones, or otherwise as a result of
this Agreement. 

    2.  Repayment by Jones: Upon the occurrence of a Payment Event, Jones shall immediately pay to
the Company the cumulative amount of all the payments made by the Company to Jones or for his benefit pursuant to this Agreement. 

    3.  General Provisions: This Agreement shall be governed by and construed in accordance with the
laws of the State of California. All notices and other communications required or permitted hereunder shall be in writing and may be given by (a) personal delivery, (b) certified mail,
postage prepaid, return-receipt requested, (c) courier service, fully prepaid for next business day delivery, or (d) facsimile. Any such notice shall be properly addressed to the address
of the parties set forth on the signature page hereof and shall be deemed to have been given (i) if personally delivered, when delivered, (ii) if by certified mail, return-receipt
requested, when delivered or refused, (iii) if by courier service, on the next business day following deposit, cost prepaid, with Federal Express or similar private carrier, or (iv) if
by facsimile, instantaneously upon confirmation of receipt of facsimile. The Company or Jones may change their address by giving notice of the same in accordance with this paragraph. The 

 

term "business day" shall mean a day on which national banks are open for business in San Francisco, California. 

    4.  Acknowledgement by Jones: THIS AGREEMENT, THE LOAN AGREEMENT, THE DEED OF TRUST, ALL OTHER
COMPANY LOAN DOCUMENTS, AND ALL RELATED DOCUMENTATION ARE EXECUTED VOLUNTARILY AND WITHOUT ANY DURESS OR UNDUE INFLUENCE ON THE PART OF OR ON BEHALF OF THE PARTIES HERETO, WITH THE FULL INTENT OF
CREATING THE OBLIGATIONS AND SECURITY INTERESTS DESCRIBED HEREIN AND THEREIN. THE PARTIES ACKNOWLEDGE THAT: (a) THEY HAVE READ SUCH DOCUMENTATION; (b) THEY HAVE BEEN REPRESENTED IN THE
PREPARATION, NEGOTIATION AND EXECUTION OF SUCH DOCUMENTATION BY LEGAL COUNSEL OF THEIR OWN CHOICE; (c) THEY UNDERSTAND THE TERMS AND CONSEQUENCES OF THIS AGREEMENT, THE EMPLOYEE LOAN AGREEMENT,
THE DEED OF TRUST, AND ALL RELATED AGREEMENTS AND DOCUMENTATION AND THE OBLIGATIONS THEY CREATE; AND (d) THEY ARE FULLY AWARE OF THE LEGAL AND BINDING EFFECT THEREOF. 

    IN
WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written. 

	

/s/ DENNIS H. JONES   
 DENNIS H. JONES	
 	

COMMERCE ONE, INC.,

a Delaware corporation
	

 	
 	

By:	
 	

/s/ MARK B. HOFFMAN   

	 	 	Its:	 	Chairman & CEO

2

QuickLinks

Exhibit 10.24

EMPLOYEE LOAN AGREEMENT

FORM OF BOFA INDIVIDUAL LOAN AGREEMENT

Exhibit B

INDEMNITY AGREEMENT SECURED BY DEED OF TRUST

Exhibit D

TAX MATTERS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]